CONFIDENTIAL  
The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such 
disclosure is required to initiate the study, to conduct study -related activities, or to comply with national, state, or local laws and 
regulations . Written authorization from the coordinating site and sponsor is required for disclosure otherwise.  
PT-PhI-II v05.22.[ADDRESS_34060] :  Patients with IDH1 Positive Recurrent 
Grade II Glioma Enroll ed in a Safety and 
Immunogenicity Study of T umor -Specific Peptide 
Vaccine  
 
Document Date:  2017- 10-11 
 
[STUDY_ID_REMOVED]  
 
  
PT-PhI-II v05.22.[ADDRESS_34061] :  Patients with IDH1 Positive Recurrent 
Grade II Glioma Enroll ed in a Safety and 
Immunogenicity Study of T umor -Specific Peptide 
Vaccine  
 
 Sponsor:  PI – Duke Cancer Institute   
 Funding 
Source:  NIH Grant   
 Protocol 
Source:  PI - Duke Cancer Institute   
 Duke IRB#:  Pro00054746   
 IND#:  [ZIP_CODE]   
 
Principal Investigator  
[INVESTIGATOR_34480], MD, PhD  
[EMAIL_560]   
Sub-Investigator(s)  
Gary Archer, Ph.D.  
[EMAIL_561]  
 
Annick Desjardins, M.D.  
[EMAIL_562]  
 
Henry Friedman, M.D.  
[EMAIL_563]  
 
Darell Bigner, M.D.  
[EMAIL_564]  
 
John Sampson, M.D., Ph.D.  
[EMAIL_565]  
 Dina Randazzo, D.O . 
[EMAIL_566]  
 
Elizabeth Reap, Ph.D.  
[EMAIL_567]  
 
Peter Fecci, M.D., Ph.D. 
[EMAIL_568]  
 Hai Yan, M.D., Ph.D. 
[EMAIL_569]  
 Brian Soher, Ph.D.  
[EMAIL_570]  
  
Statistician  
James E. Herndon II, Ph.D. 
[EMAIL_571]  
 
Lead Study Coordinator  
Sarah Woodring  
[EMAIL_572]  
 Regulatory Coordinator  
Rachel Hesler, Ph.D.  
[EMAIL_573]  
 Therapeutic Material Manufacture 
Manager  
Gary Archer, Ph.D.  
[EMAIL_574]  
 
Data Manager  
Eric Lipp  
[EMAIL_575]  
 
 
   
Original version:  20140718   
Amended version 1:  201508 31 for IND Submission  Updated information  in Figure 4 and in 
paragraph describing Figure 4 and 
inserted reference (Section 7.2.4 ); Added 

PT-PhI-II v05.22.[ADDRESS_34062]# (Section 7.2.6 ); Inserted references 
(Section 9.2); Updated the study drug 
manufacturing company (Section 10.3); 
Corrected and updated reconstitution 
information of the study drug (Section 
10.4.2); Updated references (Section 17); 
removed Td manufacturer name 
(Sections 9 and 10). 
Amended version2:  20151005 for FDA modifications  
20151216  for IRB AMD002 Removed the saline injection to the 
contralateral leg (Section 10.4.1); 
Removed reference to femoral artery for 
administering vaccines (Sections 9.1 and 
10.4.2); Added CBC and CMP blood draw 
time point in the table of scheduled 
assessments for leukapheresis screening 
with ionized calcium and pregnancy 
testing per Apheresis practice in footnote 
(Sect ion 12); Clarified “continues to do 
well” by [CONTACT_34522] 
(Section 12.7.3); More clearly defined the 
definition of unacceptable toxicity 
(Sections 8, 9.1.1 , & 15.4.1); Updated the 
definition of SAE to match 21CFR312.23 
(Section 13.2); Added the FDA for all 
adverse event reporting (Section 13.2.1); 
Corrected mis -numbering of inclusion 
criteria (Section 11.1 ); Added the 
exclusion of subjects unable to undergo MRI (Sections 11.2  & 12.8.2); Removed 
the word “transmural” from the 4
th 
exclusion criterion (Section 11.2); 
Removed ACD description of red top 
tubes (Section 12 ); Added an additional 
clinic visit with blood work to assess for 
delayed toxicity [ADDRESS_34063] 
vaccine (Section 12). 
Amended version 3  20151216 for IRB  AMD002  Removed exploratory objective 
comparison to historical controls (Section 
8); Better described evaluable subjects 
(Sections 9.4 and 15.4.2); Updated 
location of paper documents (Section 0 ); 
Changed DLT to unacceptable toxicity 
(12.6.1 );  Removed statistical estimate 
(Section 15.4.2 ) 
Amended version [ADDRESS_34064]. Fecci  & [CONTACT_34590]  
to cover page.  
Typographical error corrected in Section 
11 for inclusion criterion on KPS score 
from 60 to 70%.    
Changed wording from “recurrent” to “progressive” (Sections 8, 9, 11, 12, and 
15). 
Removed the prior chemotherapy 
exclusion criterion (Section 11). 
Amended version 5  20160517 for IRB AMD010  Updated eligibility criterion on pregnancy 
testing to within 72 hours prior to 
leukapheresis (Section 11). 
Amended version 6 [ZIP_CODE] 519 for IRB AMD 011 Clarified diff erence between Td booster 
and pre- conditioning by [CONTACT_34523]  (Sections 6, 9, 
10, & 12); Allowed subjects that transition 
to a higher grade glioma to continue on vaccines monthly during SOC XRT/TMZ 
(Sections 6, 8, 9, 12, and 15
); Updated 
immune monitoring blood work and 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 3 
 CONFIDENTIAL  
 biomarker testing  and removed urine 
sampling  (Sections  6, 8, 9 12, & 15); 
Added genomic analyses (Sections 8 , 9,  
12, and 15); Added MRS for 2HG 
measurements (Section s 6, 8, 9, 12 & 
15); Changed wording from specifically 
study coordinator to study team (Section 
9); Included standard language for 
leukapheresis preparation (Section 12); 
Increased t he dexamethasone from 2 mg 
to 4 mg max (Section 12); clarified KPS 
and physical exam to occur during standard BTC visit with the Td pre -
conditioning (Section 12); clarified tumor 
sampling for IHC analysis (Section 12); added language regarding antihistamine 
usage (Section 12
); Included SOC 
language for XRT/TMZ and adjuvant TMZ 
in the appendices as a reference 
(Sections 18.4 & 18.5). 
Amended version 7  [ZIP_CODE] 808 for IRB AMD01 5 Adjusted timin g of immune monitoring 
and genomic proteomic analysis in those 
who’ve transformed to a higher grade 
(Sections 6, 9.4, and 12); Clarified the 
description of study procedure following 
consent (Section 9 ); Clarified pregnancy 
testing and MRIs in table of events as 
well as  pathology testing (Section 12); 
Corrected error in timing of vaccine #1 
(Section 12); allowed for every 3 month 
MRI in low grade setting (Section 9 and 
12); Updated screening examination to 
match current practice and updated location of paper CRFs (Section 12); and 
Corrected error  that vaccine #3 is actually 
given on day 29 not day 30  (Sections 6, 
9, and  12). 
Amended version 8  2016 1128 for IRB AMD0 23 Formatted for FDA electronic submission; 
Changed the lead study coordinator and regulatory coordinator; Reformatted Table 
2: Screening and On-Study Tests and 
Procedures  (Section 
12); Clarified that 
vaccine will be given on day 22 (+2), not 
day 21 (+/ -2) of monthly cycles of TMZ  
because vaccine cannot be given on the 
same day as TMZ (Section 6, 
throughout ); Clarified that Single- Voxel 
MR will be d one before Td booster 
(Section 6, Section 9.5); Removed 
requirement that l eukapheresis be 
performed within 2 weeks of consent 
(Sect ion 9.1, Section 12); Corrected 
guidelines for dose  delay,  reduction , and 
discontinuation to fit 21- day TMZ , not 
standard 5- day TMZ  (Section 18.5.2) ; 
Grade 3 subjects receiving RT/TMZ can 
delay TMZ more than a week without coming off study (Section 18.5.1); 
Corrected CTQA to the new name [CONTACT_34586] 
(Section 4, Section 14.2); Immunization 
mixture will be given half in right groin 
and half in left groin for each vaccine 
(Section 9.1, Section 10.4.2, Table  2
); 
Changed SOC abbreviation to standard 
of care, not Safety Oversight Committee 
(Section 13.3)  
Amended version 9  2017010 6 for IRB AMD027  Added additional MRS time points 
(Sections 6, 9.1, 9.5, 12); Correct ed MRS 
data acquisition time from 30 minutes  to 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 4 
 CONFIDENTIAL  
 1-2 hours (Section 9.5); Baseline MRS is 
before PEP IDH1M  vaccine #1 (Section  9.5) 
Amended version 10  201701 27 for IRB AMD030  Removed recommendation that the 
needle be 25 gauge for injection of study 
vaccine because it is too narrow a bore 
for the vaccine (Section 10.4.2); Added 
that EMLA ® cream, or equivalent topi[INVESTIGATOR_34481], can be offered to subjects who 
experience local pain at the injection site 
(Section 12.8.2); Corrected the number of 
patients to 24 in the Study Schema 
(Section 6); Testing of leukapheresis 
blood for HIV, hepatitis, and syphilis was 
re-moved (Section 12.8.2 ) 
Amended version 11  [ZIP_CODE] 215 for IRB AMD03 5 Added immune monitoring time point at 
vaccine #6 (Section s 6, 9.1, and 12) 
Amended version 12  20170223  for IRB AMD03 7 Changed Princip al Investigator (title page, 
Section 13.2.1 ) 
Amended version 13  20171011  for IRB AMD054  Primary objective wording changed from 
“proportion” to “percentage” (Sections 8 
and 15.4.1) ; Changed wording of the 
timing of the Td from “12- 24 hours” before 
vaccine #1 to “one day ” before (Sections  
6, 9.1, 10.4.1, and 12); Clarified 
documentation of review of aggregate 
summary of AE information (Section 
13.1.1) ; Added that providers will take 
pi[INVESTIGATOR_34482]-op time point and at other time 
points at discretion of physician (Section s 
9 and 12); Added collection of research 
blood at  end of vaccine treatm ent (1 
month after vaccine #[ADDRESS_34065] ) (Section  12): Changed total 
enrollment from [ADDRESS_34066] 6 vaccines at 20 
(Section s 6 and 15.4.2 ) 
Pro00054746: RESIST Study  
Version: [ADDRESS_34067] OF ABBREVIATIONS  ........................................................................................................... 6 
5 PROTOCOL SYNOPSIS AND SUMMARY  .................................................................................. 9 
6 STUDY SCHEMA  ........................................................................................................................ 10 
7 BACKGROUND AND SIGNIFICANCE  ....................................................................................... 11 
7.1 Study Disease  ......................................................................................................................... 11 
7.2 Study Agents  ........................................................................................................................... 12 
7.2.1 PEP IDH1M .......................................................................................................................... 12 
7.2.2 GM-CSF .......................................................................................................................... 12 
7.2.3 Montanide ISA 51 (Incomplete Freund’s Adjuvant)  ........................................................ 12 
7.2.4 Tetanus -diphtheria toxoid (Td)  ........................................................................................ 12 
7.2.5 Pre-clinical experience  .................................................................................................... 14 
7.2.6 Clinical experience  .......................................................................................................... 16 
7.3 Study Purpose and Rationale  .................................................................................................  17 
7.3.1 Temozolomide, Lymphopenia, and Homeostatic Proliferation  ....................................... 17 
7.3.2 Peptide Vaccines for Cancer  ........................................................................................... 19 
7.3.3 Summary of Study Purpose/Rationale  ............................................................................ 20 
8 OBJECTIVES AND ENDPOINTS  ............................................................................................... 21 
9 INVESTIGATIONAL PLAN  .......................................................................................................... 22 
9.1 Study Design  ........................................................................................................................... 22 
9.1.1 Definition of Unacceptable Toxicity  ................................................................................. 23 
9.1.2 Concomitant Medications  ................................................................................................ 23 
9.2 Rationale for Selection of Dose, Regimen, and Treatment Duration  ...................................... 23 
9.3 Rationale for Correlative Studies  ............................................................................................ 23 
9.4 Rationale for Genomic Proteomic Analyses  ........................................................................... 24 
9.5 Single -Voxel MR Spectroscopy  ............................................................................................... 24 
9.6 Definition of Evaluable Subjects, On Study, and End of Study  ............................................... 25 
9.7 Early Study Termination  .......................................................................................................... 25 
10 STUDY DRUG ............................................................................................................................. 26 
10.1 Names, Classification, and Mechanism of Action  ............................................................... 26 
10.2 Packaging and Labeling  ...................................................................................................... 26 
10.3 Supply, Receipt, and Storage  ............................................................................................. 26 
10.4 Dispensing, Preparation and Administration  ....................................................................... 26 
10.4.1  Td ................................................................................................................................ 26 
10.4.2  PEP IDH1M Vaccine with GM- CSF and Montanide ISA 51  ............................................ 26 
Pro00054746: RESIST Study  
Version: [ADDRESS_34068](s)  ............................................................................................ 33 
12.6.1  Criteria for Early Withdrawal  ....................................................................................... 33 
12.6.2  Follow -up Requirements for Early Withdrawal  ............................................................ 34 
12.6.3  Replacement of Early Withdrawal(s)  ........................................................................... 34 
12.7 Study Assessments  ............................................................................................................. 34 
12.7.1  Medical History  ............................................................................................................ 34 
12.7.2  Physical Exam  ............................................................................................................. 34 
12.7.3  Use of Antihistamines .................................................................................................. 34 
12.7.4  Radiologic Evaluations  ................................................................................................ 35 
12.8 Risk/Benefit Assessment  .................................................................................................... 35 
12.8.1  Potential Benefits  ........................................................................................................ 35 
12.8.2  Potential Risks  ............................................................................................................. 35 
13 SAFETY MONITORING AND REPORTING  ............................................................................... 37 
13.1 Adverse Events  ................................................................................................................... 37 
13.1.1  Reporting of AEs  ......................................................................................................... 38 
13.2 Serious Adverse Events  ...................................................................................................... 38 
13.2.1  Reporting of SAEs  ....................................................................................................... 38 
13.3 Safety Oversight Committee ............................................................................................... 38 
14 QUALITY CONTROL AND QUALITY ASSURANCE  .................................................................. 39 
14.1 Monitoring  ............................................................................................................................ 39 
14.2 Audits  .................................................................................................................................. 39 
14.3 Data Management and Processing  ..................................................................................... 39 
14.3.1  Study Documentation  .................................................................................................. 39 
14.3.2  Data Management  ....................................................................................................... 40 
14.3.3  Data Management and Data Verification  .................................................................... 40 
14.3.4  Coding of Adverse Events  ........................................................................................... 40 
14.3.5  Study Closure  .............................................................................................................. 40 
15 STATISTICAL METHODS AND DATA ANALYSIS  .................................................................... 41 
Pro00054746: RESIST Study  
Version: [ADDRESS_34069] Radiation Therapy  ............................................................................................... 79 
18.5 Temozolomide Therapy  ...................................................................................................... 80 
18.5.1  Concurrent TMZ and RT  ............................................................................................. 80 
18.5.2  Guidelines for 21- day TMZ Therapy  ........................................................................... 80 
 
  
Pro00054746: RESIST Study  
Version: [ADDRESS_34070] dose adjuvant 
TMZ (200 mg/m2/5d) and dose- intensified TMZ (100 mg/m2/21d).  ...................................................... [ADDRESS_34071]- dose TMZ (200 mg/m2/5d) and dose- intensified TMZ 
(100 mg/m2/21d).  .................................................................................................................................. [ADDRESS_34072] OF TABLES  
Table 1. Objectives and Endpoints  ............................................................................................................. 21 
Table 2. Screening and On -Study Tests and Procedures  .......................................................................... 31 
Table 3. Conditions under Which Accrual will be Suspended  .................................................................... 42 
Table 4. Probability of Accrual Suspension as a Function of the True Unacceptable Toxicity Rate  .......... 42 
Table 5: Temozolomide Dosing Interruption or Discontinuation during Concomitant Radiotherapy  .......... 80 
Table 6. Dose Modifications of Temozolomide during Radiation Therapy  ................................................. 80 
Table 7. Criteria to Resume Temozolomide after Radiation  ....................................................................... 81 
Table 8. Temozolomide Dose Delay, Reduction, or Discontinuation During 21- day Treatment  ................ 81 
  
Pro00054746: RESIST Study  
Version: [ADDRESS_34073] Aspartate Aminotransferase  
AT Ambient Temperature  
BBB Blood Brain Barrier  
β-HCG  Beta-Human Chorionic Gonadotropin  
BMT  Bone Marrow Transplant  
BTC Brain Tumor Center  
BUN  Blood Urea Nitrogen  
Ca++ Calcium  
caBIG®  Cancer Biomedical Informatics Grid  
CAMRD  Center for Advanced MR Development  
CAR  Chimeric Antigen Receptor  
CBC  Complete Blood Count  
CCL3  C-C motif Chemokine Ligand 3  
cDNA  Complimentary Deoxyribonucleic Acid  
CFA Complete Freund’s Adjuvant  
CFC Cytokine Flow Cytometry  
CLIA  Clinical Laboratory Improvement Act  
CMP  Comprehensive Metabolic Panel  
CNC  Clinical Neurologic Change  
CNS  Central Nervous System  
CPC  Cancer Protocol Committee  
CIMP  CpG-Island Methylator Phenotype  
CRF Case Report Form  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTL Cytotoxic T -Lymphocyte  
DAR  Drug Accountability Record  
DBTIP  Duke Brain Tumor Immunotherapy Program  
DC Dendritic Cell  
DCCC  Duke Comprehensive Cancer Center  
DCI Duke Cancer Institute  
DOB  Date of Birth  
DSMB  Data and Safety Monitoring Board  
DSMP  Data and Safety Monitoring Plan  
DTH Delayed -type Hypersensitivity  
DUHS  Duke University Health System  
EAE Experimental Autoimmune Encephalomyelitis  
EBRT  External Beam Radiation Therapy  
eCRFs  Electronic Case Report  Forms  
ELISA  Enzyme -Linked ImmunoSorbent Assay  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 7 
 CONFIDENTIAL  
 ELISPOT  Enzyme -linked Immunospot  
EGFR  Epi[INVESTIGATOR_34483]-CSF Granulocyte Macrophage Colony Stimulating Factor  
HIV Human Immunodeficiency Virus  
HLA Human Leukocyte Antigen  
HMG  Hemoglobin  
HMO  Health Maintenance Organization  
HPLC  High Pressure Liquid Chromatography  
IBA Ion Beam Applications  
IC Intracerebral(ly)  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDH1  Isocitrate D ehydrogenase 1  
IEC Independent Ethics Committee  
IFA Incomplete Freund’s Adjuvant  
IFN-γ Interferon -gamma  
IHC Immunohistochemistry  
IL-[ADDRESS_34074] Number  
mRNA  Messenger Ribonucleic Acid  
MRS  Magnetic Resonance Spectroscopy  
MTD  Maximally Tolerated Dose  
NA Non-adherent  
NCI CTC  National Cancer Institute Common Toxicity Criteria  
NIH National Institutes of Health  
NK Natural Killer  
OARC  Office of Audit, Risk, and Compliance  
OS Overall Survival  
PBL Peripheral Blood Lymphocyte  
PBMC  Peripheral Blood Mononuclear Cells  
PBS Phosphate -Buffered Saline  
PET Positron Emission Tomography  
PD Progressive Disease  
PHA Phytohemagglutinin  
Pro00054746: RESIST Study  
Version: [ADDRESS_34075]-Translational Modifications  
QC/QA  Quality Control/Quality Assurance  
R-2HG R-2-hydroxyglu tarate  
RANO  Revised Assessment in Neuro -Oncology  
RDSPs  Research Data Security Plans  
RECIST  Response Evaluation Criteria in Solid Tumors  
reGBM  Recurrent Glioblastoma  
reLGG  Recurrent Low Grade Glioma  
RIO Research Integrity Office  
RNA  Ribonucleic Acid  
RT Radiation Therapy  
RT-PCR  Reverse Transcriptase  Polymerase Chain Reaction  
SAE Severe Adverse Event  
scFV  Single Chain Variable Antibody  Fragment  
SFC Spot-Forming Cells  
SOC  Standard of care  
SOP  Standard Operating Procedure  
SPECT  Single Photon Emission Computed Tomography  
TCA Trichlor oacetic Acid  
TCR T cell Receptor  
Td Tetanus -diphtheria toxoid  
TGF-β Transforming Growth Factor -β 
TMZ Temozolomide  
TNF-α Tumor Necrosis Factor -α 
Tregs Regulatory T cells 
TTP Time to Progression  
TTRNA  Total Tumor mRNA  
VDLNs  Vaccine -site Draining Lymph Nodes  
WHO  World Health Organization  
WOCBP  Women Of Childbearing Potential  
XRT Radiation Therapy  
  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 9 
 CONFIDENTIAL  
 5 PROTOCOL  SYNOPSIS AND SUMMARY  
Please see separate document (available upon request).   
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 10 
 CONFIDENTIAL  
 6 STUDY SCHEMA 
 
 
 
Figure 1. Study Schema  
 
  

Pro00054746: RESIST Study  
Version: [ADDRESS_34076] common and aggressive glioma 
with a median OS of <[ADDRESS_34077], immunotherapy promises an exquisitely precise approach and substantial evidence 
suggests that immunotherapeutic intervention can eradicate well -established tumors in mice and humans, 
even w hen tumors reside within the “immunologically privileged” brain. (See Figure 2, Figure 3, and Figure 
4)1,2,7 ,8 There i s a clear and urgent need for the development of targeted therapeutics that can improve 
outcomes  for patients with glioma without adding significant toxicity to current treatment regimens. 
Immunotherapy targeting tumor -associated antigens holds significant promise to meet this need.   
 
Figure 2. Highly reactive transferred cells traffic to brain and destroy tumor deposit in melanoma 
patients.  Arrows represent location of melanoma metastases. (From Johnson et al ., Blood 2009)[ADDRESS_34078] -derived antitumor T cells treat lesions in the brain.  Arrows represent location of 
metastases. (A&C) Pretreatment (B) 14 months after cell transfer (D) 6 m onths after cell transfer. (From 
Hong et al., Clinical Cancer Research)2 
 

Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 12 
 CONFIDENTIAL  
  
Figure 4. Genetically engineered antitumor T cells treat lesions in the brain  Arrows represent location 
of metastases. (A&C) Pretreatment (B) 6 months after cell transfer (D) 30 months after cell transfer. (From 
Hong et al., Clinical Cancer Research)[ADDRESS_34079] of a 25 amino acid peptide (PEP IDH1M) and the adjuvant s GM-CSF and 
Montanide ISA -51. 
7.2.1  PEP IDH1M  
PEP IDH1M is a 25 amino acid peptide that spans the mutated region of IDHR132H.  
7.2.2  GM-CSF 
Recombinant GM- CSF, Leukine® (sargramostim), is a normal human cytokine that increases the 
number and function of granulocytes (neutrophils, eosinophils, and basophils) and monocytes. It has been 
FDA-approved for clinical use for more than a decade. It is usually used follo wing induction chemotherapy 
in older adult patients with AML to shorten time to neutrophil recovery , but has also been used previously 
as a vaccine adjuvant .9 It is contra- indicated in  patients with excessive leukemic myeloid blasts  (which we 
would not expec t in the disease under study in this protocol) , patients with known hypersensitivity to GM -
CSF, yeast -derived products, or any component of Leukine. Serious allergic or anaphylactic reactions have 
been reported with Leukine.  
7.2.3  Montanide ISA 51  (Incomplete Fr eund’s Adjuvant)  
Montanide ISA 51 or Incomplete Freund’s Adjuvant  (IFA) is a water -in-oil (w/o) emulsion with 
immunomoadjuvant activity. Montanide ISA 51 enhances the immune system’s CTL response against 
antigen(s) in vaccines.  Peptide vaccinations employing GM- CSF and Montanide ISA -[ADDRESS_34080] 
generally been well tolerated in human patients in numerous phase I -III trials . 
7.2.4  Tetanus -diphtheria  toxoid (Td)  
The current use of Td toxoid is for active immunization in children and adults against infection with the 
bacteria Clostridium tetani and Corynebacterium diphtheria. Tetanus infection is manifested primarily by 
[CONTACT_34524] a potent exotoxin released by C. tetani. Diphtheria is an acute toxin-
mediated infectious disease caused by [CONTACT_34525] C. diphtheriae. Protection against disease is due 
to the development of neutralizing antibodies to the diphtheria toxin. Td toxoids adsorbed are readily available as several approved administrations [i.e. Daptacel (DTaP), Inf anrix (DTap), Tenivac (Td adult), 
Boostrix (Tdap)
10. Protection against disease is due to the development of neutralizing antibodies to the 
tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by [CONTACT_34526], is considered the minimum protective level. A level ≥0.1 IU/mL by [CONTACT_34527]
11. 
A serum diphtheria antitoxin level of 0. 01 IU/mL, measured by [CONTACT_34526], is the lowest level 
giving some degree of protection; a level of 0.1 IU/mL by [CONTACT_34528]. Diphtheria antitoxin levels ≥1.0 IU/mL by [CONTACT_34529]- term protection.  
 

Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 13 
 CONFIDENTIAL  
 Following deep s.c./i.m. administration of the tetanus toxoid vaccine, toxoid molecules are taken up at 
the vaccination site by [CONTACT_34530], which are professional antigen- presenting cells. Within these cells, 
they are processed through the endosomal pathway  (involving the phagolysosome) where  they are bound 
to MHC type II molecules on the surface of DCs. The MHC II:toxoid complex then migrates to the cell 
surface. While this process is happening within the cell, the now activated mature DC at the vaccine site 
migrates along lymph channels to the draining lymph node where they encounter naive TH2 cells, each 
with their own unique TCR. Identifying and then binding of the MHC II:toxoid to the specific TH2 receptor then activates the naive T cell, causing it to proliferate. Simultaneously, toxoid molecules not taken up by 
[CONTACT_34531] B 
cells, each with their own unique B -cell receptor (BCR). Binding to the B cell through the specific 
immunoglobulin receptor that recognizes tetanus toxoid results in the internalization of toxoid, processing 
through the endosomal pathway and presentation on the cell surface as an MHC II:toxoid complex, similarly 
to DCs undergoing the same process
12.  
 
These two processes occur in the same part of the lymph node with the result that the B cell with the 
MHC II:toxoid complex on its surface now comes into contact [CONTACT_34532]2 whose receptors are 
specific for this complex. The proc ess, termed linked recognition, results in the TH2 activating the B cell to 
become a plasma cell with the production initially of IgM, with a later switch to IgG antibodies produced. 
Additionally, a subset of these B  cells becomes memory cells12. 
 
The novelty of using Td toxoid vaccination lies in the ability of this potent recall antigen to enhance 
antitumor responses as part of a cancer vaccination protocol. Td toxoid induces  an inflammatory milieu 
within the intradermal vaccine site, thereby [CONTACT_34533] -specific DCs. 
Additionally, in the context of vaccinating the host with tumor -derived peptides, conditioning the vaccine 
site with Td toxoid has demonstrated enhanced immunogenicity with these peptides.  
 
Our data from the ATTAC clinical trial (Duke IRB Protocol # Pro00003877) demonstrating the capacity 
to enhance DC migration to VDLNs via Td pre- conditioning of the vaccine site offer potential therapeutic 
interventions whereby [CONTACT_34534]. In a completed randomized clinical trial, we found that migration of injected DCs to VDLNs following vaccine site pre- conditioning with Td toxoid was 
significantly increased compared to controls and that the efficiency of DC migration was strongly associated with clinical outcomes of patients with newly -diagnosed GBM, the most fatal type of mali gnant brain 
tumors
13. To address this observation, we took our Td pre- conditioning platform back into the preclinical 
setting using transgenic mouse models and were able to corroborate the effects of Td pre- conditioning on 
increasing the lymph node homing of intradermally administered DCs. Moreover, Td administration at a single vaccine site increases the migration of a bilateral DC vaccine to both inguinal lymph nodes. 
Regardless of the side of the Td intradermal skin prep, DC migration to bilateral inguinal VD LNs was equally 
increased, supporting a systemic response to recruit peripherally administered DCs.  
 
Our Td pre- conditioning platform in the context of DC vaccination also elicited superior anti -tumor 
responses compared to controls receiving DC vaccines without Td pre- conditioning. In our clinical trial, 
patients with newly -diagnosed GBM who were administered the Td skin prep before DC vaccination 
revealed significantly longer progression- free and overall survival rates compared to the control cohort. In 
evaluating the relationship between DC migration and clinical responses, we observed a modest positive correlation between levels of DC migration and survival. In our preclinical model, Td pre- conditioning prior 
to vaccination with tumor antigen- specific D Cs dramatically suppressed the growth of established and 
highly aggressive B16- F10/OVA tumors. The use of Td with a DC vaccine increased antitumor responses 
in an antigen- specific manner, as non- specific DC vaccines were not potentiated with Td pre- conditi oning. 
Furthermore, in a challenge setting, where mice are administered the treatment platform prior to challenge with tumor inoculation, Td pre- conditioning at the vaccine site induced a significant survival benefit 
compared to controls.  
 
For this clinical trial evaluating PEPI[INVESTIGATOR_34484]1M, we are also proposing to use Td as an adjuvant based on 
the pre-  clinical data described below. Here, mice were immunized with 25mer mutant and wildtype peptides 
with two clinically relevant adjuvants: granulocy te-macrophage colony stimulating factor (GM- CSF), a 
Pro00054746: RESIST Study  
Version: [ADDRESS_34081] administered at the vaccine site and tetanus -preconditioning.  Immunogenicity of each 
adjuvant/vaccine combination was measured via IFNγ ELISpot; administration of imiquimod at the site of 
vaccination results in a more robust mutant -specific immune response compared to GM- CSF, Notably, 
immunogenicity of the mutant peptide in mice that received imiquimod emulsified in IFA/IFA/IFA is 
comparable to the immune response seen in mice that received CFA/IFA/IFA, a treatment course with 
widely known strong adjuvant activity ( Figure 5). 
 
 
Figure 5. Tetanus  pre conditioning, imiquimod and GM -CSF increases the number of IDH1 mutant 
specif ic T cells after vaccination.  Mice were immunized with (three weekly 100 ug of peptide emulsified 
in IFA/IFA/IFA), and immunogenicity was measured via IFNγ ELISPOT against both the wild- type and 
mutant 25mer peptides.  
7.2.[ADDRESS_34082] developed a functional murine homologue (Figure 6) of the human IDH1R132H mutant enzyme, 
cloned syngeneic murine gliomas that express this mutation, mapped peptide sequences specific to this 
mutation in either species  (Figure 7), and demonstrated mutation- specific immunogenicity of these peptides 
(Figure 8 and Figure 9). Preliminary ELIS pot data from our laboratory demonstrates that splenic 
lymphocytes isolated from mice immunized with peptides of various lengths  containing the IDH1R132H 
mutation (PEP IDH1M) are activated by [CONTACT_34535], demonstrating both specificity and 
immunogenicity ( Figure 10). Vaccination with PEP IDH1M in 3 different strains of mice has produced no 
toxicity.  

Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 15 
 CONFIDENTIAL  
  
Figure 6. The murine homologue of the IDH1R132H mutation is functional.  Murine cells were 
transduced with the IDH1R132H mutation or left untransduced as controls. Whole cell extracts were 
submitted for quantification of R -2-hydroxyglutarate by [CONTACT_29864] -negative electrospray ionization- MS/MS. Values 
were normalized to total protein levels in each sample.  
 
 
Figure 7. Human IDH1R132H protein sequence and human  and mouse wild type sequences.  The 
mutation is highlighted in yellow. Purple highlights nearest sequence difference between human (S) and 
mouse (T) protein which is not included in the 25mer IDH1R132H (PEPI[INVESTIGATOR_34484]1M) peptide. PEPI[INVESTIGATOR_34484]1M  (red 
text) is identical between human and mouse.  
 
 
Figure 8. PEPI[INVESTIGATOR_34484]1M vaccination is immunogenic and specific in several mouse strains.  Different 
mouse strains were immunized weekly for 3 weeks with PEPI[INVESTIGATOR_34485]1 in CFA. After 7 days splenic 
lymphocytes were derived and stimulated with mutant or wildtype IDH1 peptide and IFNy secretion was 
assessed by [CONTACT_34536]. *p<0.[ADDRESS_34083] 
 

Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 16 
 CONFIDENTIAL  
  
Figure 9. PEPI[INVESTIGATOR_34484]1M vaccination is immunogenic and specific in the context of human HLA.  HLA-
A2 Transgenic mice were immunized weekly for 3 weeks with 25mer or 9mer length peptides in CFA 
containing PEPI[INVESTIGATOR_34485]1. 9mer peptides consisted of a peptide mix of 9 different peptides all spanning the 
IDH1R132H mutation. After 7 days, splenic lymphocytes were derived and stimulated with mutant or wild 
type IDH1 25mer peptide and IFNy secretion was assessed by [CONTACT_34536].  
 
 
Figure 10. Splenocytes from mice immunized with different lengths of mutant IDH1 peptides.  Mice 
were immunized weekly for 3 weeks with different length peptides in CFA containing the IDH1R132H 
mutation. After 7 days, splenic lymphocytes were derived and stimulated with the 25mer  mutant peptide 
(PEP IDH1M) or wildtype IDH1 peptide and IFNy secretion was assessed by [CONTACT_34536].  
7.2.[ADDRESS_34084] tumors in the brain without any toxicity . EGFRvIII is a tumor -specific mutation of the 
epi[INVESTIGATOR_34486].14 
Because the wild type sequences of human and mouse overlap adjacent to the EGFRvIII mutation, we 

Pro00054746: RESIST Study  
Version: [ADDRESS_34085] its immunogenicity  without 
concerns that the results would be influenced by [CONTACT_34537] .15 Using this approach, w e 
demonstrated that a  peptide vaccine (PEPvIII) specific for  the tumor -specific mutation EGFRvIII is capable 
of eliciting EGFRvIII -specific immune responses in mice with orthotopic gliomas .[ADDRESS_34086] all patients and EGFRvIII -expressing tumor cells were nearly 
universally eliminated without attendant toxicity.16-18 Based on these data, this EGFRvIII- targeted vaccine 
is now being tested in an international Phase III  trial ([STUDY_ID_REMOVED]) . Unfortunately, EGFRvIII is 
heterogeneously expressed and tumors recur as a result of outgrowth of the EGFRvIII negative tumor cells.[ADDRESS_34087] shown that following periods of 
lymphopenia, immune responses can be markedly enhanced.19-23 Probably as a result of a surge in 
cytokines (IL- 7, IL- 15) in response to lymphopenia, lymphocytes undergoing homeostatic proliferation enjoy 
a reduced activation threshold,24,[ADDRESS_34088] dose 
adjuvant TMZ (200 mg/m2/5d) and dose -intensified TMZ (100 mg/m2/21d).  Standard  dose TMZ induces 
Grade 2 lymphopenia in 100% of patients (<800 cells/uL; blue line) and transient Grade 3 lymphopenia in 40% of patients. Sustained Grade 3 lymphopenia (<500 cells/uL; red line) was induced by [CONTACT_2715]- intensified 
TMZ cycle #[ADDRESS_34089] Dose TMZ (200mg/m2/5d) (N=5)
Dose-Intesified TMZ (100mg/m2/21d) (N=8)
Grade 3 (<500 cells/ µL)Grade 2 (<800 cells/ µL)Absolute Lymphocyte Count (Day 21)
(cells/µL blood)
Pro00054746: RESIST Study  
Version: [ADDRESS_34090] produced dramatic clinical responses21,29 -32, 
along with some autoimmune toxicity, in patients with advanced malignant melanoma.20,22 After 
lymphodepletion, T -cells can expand dramatically and tumor -specific T -cells can constitute up to 90% of 
the host’s T -cell repertoire and can be maintained for months ,20,[ADDRESS_34091] of TMZ 
treatment, in the context of our EGFRvIII peptide vaccine trial (now CDX -110, [COMPANY_007], Inc.), on the 
lymphocyte compartment and immunologic responses of patients with newly -diagnosed GBM un dergoing 
two different dose regimens of adjuvant TMZ. These regimens were evaluated in a randomized, Phase III 
trial (RTOG 052541). After concurrent TMZ with EBRT, patients received TMZ for either 5 days (200 mg/m2) 
or 21 days (100 mg/m2) of each 28 day cycle. 100% of patients receiving the standard 5 day schedule 
exhibited Grade 2 lymphopenia (<800 cells/uL) ( Figure 11) with nadirs occurring 14- [ADDRESS_34092] 
dose (n=5). Grade 3 lymphopenia was observed in only 1 patient with this regimen. Sustained Grade 3 
lymphopenia (<500 cells/uL) was induced in all patients receiving the [ADDRESS_34093] been able to induce and maintain potent 
EGFRvIII -specific immune responses (Figure 12 and Figure 13) in patients  with GBM receiving serial cycles 
of TMZ .[ADDRESS_34094] -dose TMZ (200 mg/m2/5d) and dose -intensified 
TMZ (100 mg/m2/21d) . All patients receiving the 21 day dose regimen developed EGFRvIII -specific 
antibodies with titers detectable at greater than 1:100,[ADDRESS_34095] been dramatically better in patients receiving the higher TMZ dose.  
 Vaccine 3 Vaccine 4 Vaccine 5 Vaccine 6 Vaccine 7 Vaccine 810,000100,0001,000,000
200 mg/m2/5d100 mg/m2/21d1 / TiterP=0.0093, Two-way 
ANOVA, repeated 
measures, For 
InteractionACTIVATE: 7/[ADDRESS_34096] II: 15/15
(P= 0.0022, 
Fisher’s exact)
Pro00054746: RESIST Study  
Version: [ADDRESS_34097]  200mg/m2/5dUndectable
UndectableDose-Intensified 100mg/m2/21dmm squaredCandida DTH Response
Pre Vaccine Dose [ADDRESS_34098]  200mg/m2/5d
UndetectableDose-Intensified 100mg/m2/21dmm squared
 
Figure 13. DTH responses to EGFRvIII vaccination.  DTH responses to EGFRvIII vaccination (Left) in 
patients receiving lymphodepletive TMZ (100 mg/m2/d x 21 days) cycles (black) were increased when 
compared with standard dosing (200 mg/m2/d x 5 days) with continued vaccination. DTH responses to the 
recall antigen Candida (Right) in patients receiving lymphodepletive TMZ (1 00 mg/m2/d x 21 days) cycles 
(black) were decreased when compared with standard dosing (200 mg/m2/d x 5 days) with continued cycles 
of TMZ.  
7.3.2  Peptide Vaccines for Cancer  
Peptide vaccines encoding minimal CD8+ CTL epi[INVESTIGATOR_34487] .43,44 However, with few several notable exceptions ,36,45-48 vaccine -based cancer immunotherapy in 
humans is in need of significant improvem ent in immunogenicity and clinical outcomes .21  
The addition of CD4+ T cell helper epi[INVESTIGATOR_34488] -tumor immunity .49 This presumption is supported by [CONTACT_34538]4+ T cell directed therapy can mediate effective anti -tumor immunity in humans and 
experimental animal s.50-52 CD4+ T helper cells deliver assistance for CD8+ effector cells by [CONTACT_34539]40- CD40L signaling pathway .[ADDRESS_34099] highlighted the use of longer peptides (15- 30 amino acids in length) instead of 
minimal CTL epi[INVESTIGATOR_322] (typi[INVESTIGATOR_897] 8- 10 amino acids) for induction of a more robust, long lived CD8+ cytotoxic 
T-cell responses in experimental animals .36,[ADDRESS_34100] toxicities occur when peptide vaccines are used in conjunction with immunostimulatory 
cytokines such as IL- 2, which are expected results of IL- 2 therapy .59 This feature of peptide vaccinations 
allows it to be used in combinatorial immunotherapeutic strategies and/or as salvage therapi[INVESTIGATOR_34489].60,61 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 20 
 CONFIDENTIAL  
 7.3.3  Summary of Study Purpose/Rationale  
Primary brain tumors are the most frequent cause of cancer death in children and young adults. GBM, 
the most malignant primary brain tumor, has a median OS of <[ADDRESS_34101], immunotherapy promises an 
exquisitely precise therapeutic approach, and substantial evidence suggests that activated T-cells can 
eradicate large tumors, even within the “immunologically privileged” brain.[ADDRESS_34102] previously 
demonstrated that EGFRvIII -specific immu ne responses could be generated in mice, and this predicted the 
ability to generate similar immune responses in humans.9,16-18,62 These were sufficient to eliminate 
orthotopic gliomas expressing a murine homologue of EGFRvIII in mice and were suffici ent to consistently 
eliminate all EGFRvIII -expressing tumors cells in mice and humans without toxicity.9,17,63,64 Based on these 
observations, our EGFRvIII -targeted vaccine is now being tested in an international Phase III trial. 
Unfortunately, EGFRvIII is heterogeneously expressed and tumors recur as a result of outgrowth of the 
EGFRvIII negative tumor cells.9 
Recently, unbiased, genome wide sequencing has been shown to be a powerful approach for  
identifying other recurring mutations like EGFRvIII. Using next -generation sequencing, we discovered 
tumor -specific mutations exclusively in codon 132 of the active site of IDH165,66 – an evolutionarily -
conserved enzyme essential to cell function.67 Further study revealed that IDH1 mutations occur in >70% 
of almost all glioma subtypes, except primary GBM. Greater than 90% of all IDH1 mutations occur from a 
substitution of histidine for arginine resulting in the highly conserved and tumor -specific mutation, 
IDH1R132H.[ADDRESS_34103] the antigen escape seen with EGFRvIII -targeted vaccines.  
Here we propose to leverage our experience targeting tumor -specific antigens to assess the potential 
of an IDH1 mutation- specific vaccine as a treatment for patients with tumors containing IDH1R132H 
mutations.   
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 21 
 CONFIDENTIAL  
 8 OBJECTIVES AND ENDPOINTS  
 
Table 1. Objectives and Endpoints  
 Objective  Endpoint  Analysis  
Primary  To assess the safety of the 
PEP IDH1M vaccine alone and in 
combination with adjuvant TMZ  
and/or XRT/TMZ  in adult patients 
with progressive, resectable 
WHO grade II gliomas  that are 
confirmed Grade II or transition to 
a higher grade glioma at the time 
of surgery.  The percentage  of patients who 
experience an unacceptable toxicity  
defined as any Grade [ADDRESS_34104] 
possibly attributed to the vaccine (or 
vaccine + TMZ  and/or RT ) that does not 
resolve to baseline with in 3 week s, any 
Grade 3 hypersensitivity reactions 
requiring steroids, any Grade 4 toxicity, 
including neurologic events not due to 
progressive disease, or any life 
threatening- event not attributable to 
concomitant medication, co- morbid event, 
or disease progression .  See Section 15.4 
Secondary  To assess the immunogenicity of 
the PEP IDH1M vaccine with 
adjuvant TMZ using ELISpot . 
 Mean difference in the number  of SFC 
per 106 lymphocytes for cells cultured 
with and without IDH1 peptide  See Section 15.5 
Exploratory  To describe  PFS and OS . 
 Proportion of patients alive without 
disease progression 6 months after initial 
vaccine treatment; m edian progression-
free survival and median overall su rvival.  See Section 15.[ADDRESS_34105] PFS or 
OS. 
 Number of SFC per 106 lymphocytes 
above pre- vaccine baseline is a predictor 
of PFS or OS See Section 15.6 
Exploratory  To estimate radiographic 
response rate prior to surgical 
resection and PFS after resection 
using RANO criteria.  Proportion of patients with radiographic 
response (complete + partial response) 
observed prior to surgical resection.  
Proportion of patients alive without 
disease progression [ADDRESS_34106]-vaccine surgery.  
 Median number of immunologic cell 
infiltrates at the time of surgery  See Section 15.6 
Exploratory  To determine if tumor -specific 
circulating DNA containing the 
c.395G>A (R132H) mutation can 
be detected in plasma before, 
during,  and after study drug 
treatment.  Detection of t umor -specific circulating 
DNA containing R132H mutation.  
Mean changes  in R132H mutation from 
baseline.  See Section 15.[ADDRESS_34107] -translational 
modifications (PTMs) using quantitative proteomic strategies 
in patient -derived samples.  Changes between baseline and surgery 
in genetic alternations, differential  protein 
expressions and post -translational 
modifications (PTMs)  See Section 15.6  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 22 
 CONFIDENTIAL  
 Exploratory  To demonstrate quantitative 
repeatable measures of 
metabolism change in IDH1+ 
gliomas via a standardized MRS 
protocol, patients will be scanned 
on the research MR scanner to 
establish same- day and 
longitudinal metabolite coefficient of variance and possible 
longitudinal metabolite changes.  Difference in levels of metabolism 
measured at same assessment.  
Changes from baseline in metabolism 
levels at each follow -up assessment.  See Section 15.6 
9 INVESTIGATIONAL PLAN  
9.1 Study D esign  
Subjects with radiographic and/or  clinical progressive and resectable Grade II glioma with expression of 
IDH1R132H from the primary tumor (initial diagnosis ) will be enrolled after signing informed consent.  After 
consent has been signed, all subject s will undergo standard of care vaccination with 0.5 mL of Td (tetanus 
and diphtheria toxoids adsorbed) intramuscularly  (I.M.)  into the deltoid muscle to ensure adequate immunity 
to the tetanus antigen. The tetanus vaccine will be obtained through Duke ICS Pharmacy .  
 Eligible subjects will undergo a 1- 2 hour leukapheresis for immune monitoring.   Within 48 hours of 
leukapheresis,  subjects will receive a vaccine site pre- conditioning as a single dose of Td toxoid (1 
flocculation unit, Lf, in a total volume of 0.4 mLs saline). This will be administered one day prior to receiving 
PEP IDH1M vaccine intradermally (i.d.) to the RIGHT gro in area (as described below).   The peptide vaccine 
is administered in the groin area approximately 10 cm below the inguinal ligament as vaccine # 1. 
Subsequent vaccines will be given on day 15 ±3 days (vaccine #2) and day 29 ±3 days (vaccine #3). These 
injections will occur without TMZ.  Each injection of the peptide vaccine will be given half on the right groin 
and half on the left groin.     
Seven to [ADDRESS_34108]’s reaction to the vaccine.  
Tumor samples from the surgical resection will be evaluate d as outlined in the Exploratory Objectives.  
Based on tissue obtained at surgical resection, s ubjects with stable histologic grade at recurrence will 
then be treated with vaccine and adjuvant TMZ  at a targeted dose of 50- 100mg/m2/d for 21 days  every 28 
days for up to 12 cycles  (please see Section 18.5 in the Appendices for TMZ) . During monthly cycles of 
TMZ, subjects will receive the vaccine on day 22 (+ 2 days ) for a maximum of 15 total vaccines (which 
includes the first 3 bi -weekly vacci nes). Patients that have transitioned to a higher Grade brain tumor  will 
receive TMZ and radiation therapy per standard of care and monthly vaccines . 
All Adverse Events will be collected from time of consent until the end of the treatment phase of the 
study. The treatment phase of the study will end  [ADDRESS_34109] vaccine  (Section 12.3) . Patients will 
be followed only for overall survival , progression- free survival, and subsequent therapi[INVESTIGATOR_34490].  For 
higher grade gliomas undergoing RT  (please see Section 18.4 in the Appendices for SOC RT ), vaccine #4 
will be given during the SOC clinic visit prior to initiating RT, and vaccine # 5 will be given 4 weeks later (± 
1 week) during RT.  Vaccine #[ADDRESS_34110] -RT TMZ, if MRI stable.  Then, subjects in this treatment group will receive vaccines monthly on 
day 22 (+2 days ) with post -RT cycles of TMZ to a maximum of [ADDRESS_34111] blood collected,  as described in Section 
12, during the following times:  prior to vaccine therapy (at leukapheresis visit), prior to surgical resection  
(at the pre- op screening visit) , prior to either RT/TMZ or first cycle of adjuvant TMZ (at SOC clinic visit)  
depending on tumor pathology , at vaccine # 6, and at End of Treatment (follow -up visit 1 month af ter vaccine 
#15; If a subject decides to stop participating in the study prior to vaccine #15, blood will be obtained at that 
time, if possible ; If a subject progresses prior to vaccine #15, blood will be obtained at that time, if possible)  
.For genomic pr oteomic analyses, blood and tumor samples will be obtained as described below in Section 
9.4. 
Subject s will be imaged with contrast -enhanced MRI according to the SOC every 10 weeks (+/ - 4 weeks)  
while on TMZ and afterward, per the treating neuro- oncologist’s recommendation. RANO criteria will be 
used for assessment of pseudoprogression and tumor progression (please see Section 12.7.3 for further 
detail) .  Subjects demonstrating definitive progression will be removed from study.  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 23 
 CONFIDENTIAL  
 In addition, to demonstrate quantitative repeatable measures of 2HG  in IDH1+ gli omas, subjects will be 
imaged using magnetic resonance spectroscopy  (MRS)  at baseline (prior to vaccine #1 following consent), 
and up to 4 times prior to surgery  (please see Section 9.5 below for further information).  
As part of standard care for these subject s, upon tumor progression, participants may undergo 
stereotactic biopsy or resection. As this is not a research procedure, consent will be obtained separately . 
Subjects that have this procedure done within the Duke University Health System may be approached to 
participate in the Duke Brain Tumor Center Biorepository study (Pro00007434) . Tissue  obtained from 
subjects who consented to the Duke Brain Tumor Center Biorepository will be used  to assess immunologic 
cell infiltration , antigen expression, and biomarkers for immunologic response.  
9.1.[ADDRESS_34112] possibly  attributed to the vaccine (or vaccine + TMZ  +/- RT) that 
does not resolve to baseline with in 3 week s, any Grade 3 hypersensitivity reactions requiring s teroids, any 
Grade 4 toxicity, including neurologic events not due to progressive disease, or any life– threatening event 
not attributable to concomitant medication, co- morbid event, or disease progression.  
Please refer to the Potential Risks Section  12.8.[ADDRESS_34113] and recorded at each study 
visit by [CONTACT_3476] . 
9.2 Rationale for Selection of Dose, Regimen, and Treatment Duration  
The PEP IDH1M vaccine dose that will be evaluated in this trial will be 500 µg with 150 µg of GM- CSF 
mixed 1:1 with Montanide ISA 51 administered intradermally  as vaccine # 1. Subsequent vaccines will be 
given on day  15 ±3 days (vaccine #2) and on day 29 ±3 days  (vaccine #3) . The same dose will be 
administered on day 22 (+ 2 days) of each monthly cycle of adjuvant TMZ  following surgical resection for 
those with confirmed Grade II . For those who transition to a higher grade glioma, they will be  undergoing 
RT (please see Section 18.4 in the Appendices for SOC RT) , thus, vaccine #4 will be given during SOC 
clinic visit prior to in itiating RT, and vaccine # 5 will be given 4 weeks later (± 1 week) during RT.  Vaccine 
#[ADDRESS_34114] -RT TMZ, if MRI 
stable.  Then, subjects in this treatment group will receive v accines monthly on day 2 2 (+ 2 days) with post -
RT cycles of TMZ to a maximum of [ADDRESS_34115] be 
presented by [CONTACT_34540] (HLA) on the surface of a tumor cell for recognition by a T cell. 
There are a tremendous number of HLA alleles with variable expression from person to person. As certain 
peptides are able to bind with much greater affinity to certain HLA alleles, the ability of one individual to 
present the IDH1 mutant peptide will be dependent upon their unique set of HLA alleles and may differ 
greatly from another individual with differing HLA. Therefore, it is critical to know the HLA type of a patient 
receiving the peptide vaccine as this may reveal if certain HLA types are associated with enhanced vaccine 
induced immune responses. Such information may suggest certain HLA types present the mutant peptide in a superior fashion and may be valuable in stratifying patients for clinical trials using this vaccine.  We 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 24 
 CONFIDENTIAL  
 intend to identify HLA types from PBMCs taken at the leukapheresis  time point.  The purpose of collecting 
these data will be to determine whether there may be immune correlates that associate with clinical 
outcomes such as PFS and OS following vaccination with the PEP IDH1M vaccine . Although this Phase I 
study is not designed to be definitive t owards this end, these analyses will provide the initial data necessary 
to adequately power future studies . Any evidence of tumor response will be determined according to the 
Duke PRTBTC SOP ( available upon request ). RANO criteria82 will be used for assessment of 
pseudoprogression. Tumor progression will need to be documented histologically, unless there are clinical 
contraindications, to exclude inflammatory responses presenting as radiographic or clinical changes, which 
could indic ate potentially toxic or therapeutic responses and not tumor progression. Patient s will be followed 
until death.  
 
9.[ADDRESS_34116] been well -established at the genetic and epi[INVESTIGATOR_34491] (e.g., closely associated with several other genes, and has a profound impact in DNA methylome), 
the effect of the IDH1 mutant on the proteomic level is unclear, thus presenting a great opportunity for understanding glioma pathogenesis and developi[INVESTIGATOR_34492]. Second, in addition to IDH1 mutations, other genetic alterations and their associated mutant peptides may serve as multi variant factors 
underlying patient treatment outcome. It is critical to have a bird’s eye view of and dissect all the genetic and peptide components that help stratify patients for clinical trials.  
 
We intend to identify genetic alterations, differential protein  expressions  or post-translational 
modifications  (PTMs)  via our comprehensive ‘inside- out’ quantitative proteomic strategies  in patient -derived 
tumor samples.  Genetic alterations, differential  protein  expressions  or PTM s that have been identified wi ll 
be further tested in all patients enrolled in this clinical trial. We propose to obtain the following specimens, 
from patients both before and after treatment, for both genomic and proteomic analyses.  
(1) Tumor tissues –  [ADDRESS_34117] ed. If available, t hese samples will be used for genomic and proteomic 
analysis.  
(2) PBCs – to determine proteomic profiling with a focus on immune system, and also for immune 
monitoring and tumor circulating DNA detection. Twenty mLs of peripheral blood (3 yellow top 
tubes)  is requested (1) before vaccine  with the leukapheresis visit , (2) at the pre-op screening visit 
before surgery, (3) At the SOC clinic visit prior to starting the 1
st cycle of TMZ  for those who are 
confirmed Grade II, or at the SOC clinic visit prior to starting RT/TMZ for those who have transitioned to a higher grade glioma, ( 4) Vaccine #6, and (5) End of Treatment (follow -up visit 1 
month after vaccine #15). If a subject decides to stop participating in the study prior to vaccine #15, 
blood will be obtained at that time (if possible).  If a subject progresses prior to vaccine #15, blood 
will be obtained at that time (if possible) .  PBMCs and plasma will be separated. Plasma will used 
for the detection of IDH1 mutation before surgery.   
These experiments will:  
- Identify genetic alterations and changes in protein before and after treatment with peptide vaccine 
in tumor cells.  
- Identify proteins showing differential expressions or PTMs in immune cells, with and without  IDH1 
mutant, and before and after IDH1 vaccination, with a potential of revealing how immune cells 
response to  IDH1 mutant, before and following vaccination.  
We will perform proteomics, exome sequencing and RNA -sequencing on the resected tumors (after 
three IDH1 vaccines). We will use patient samples before IDH1 vaccination as controls.  Radiographic and 
clinical tumor progress, as well as IDH1 mutation status in patient’s plasma will be recorded.  
9.5 Single-Voxel MR Spectroscopy  
To demonstrate quantitative repeatable measures of metabolism change in IDH1+ gliomas, patients 
will be scanned on the research MR scanner using standardized MRS protocol  to assess same- day 
repeatability and to assess longitudinal metabolite changes.  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 25 
 CONFIDENTIAL  
 The IDH1 mutation causes extreme overexpression of the onco- metabolite R -2-hydroxyglutarate (2HG) 
in all tumor cells. This can be non- invasively  measured using clinical MRS methods. 2HG is a specific 
marker for IDH1 mutated gliomas because its concentration in ‘wild’ IDH1 gliomas is below the level of 
measurement of MRS.  
Duke Radiology has  a standard protocol for 2HG measures using a proven 2HG MEGA- LASER pulse 
sequence for Siemens MR scanners and [CONTACT_34591]’s open source “Vespa” software for spectral simulation 
and fitting of the MEGA -LASER data. The protocol is available for immediate use on our research scanner  
as a part of the Duke Radiology’s Center for Advanced MR Development ( CAMRD ).  
We will assess subject s at up to 5 time points: baseline (after consent and before PEP IDH1M vaccine 
#1), and up to 4 times prior to surgery. This will provide between 6- 8 weeks of tumor/vaccine interaction. A 
typi[INVESTIGATOR_2855]  2HG protocol consists of 12- 15 minutes of anatomical MRI and ~ 15-30 minutes of MRS data 
acquisition. An IDH1+ patient can usually be processed in a 1 -2 hour  time slot.   
In order to establish same- day coefficients of variance and/or optimized acquis ition parameters , 
patients may be scanned twice within a time point . Patients will be positioned and scanned in the MR 
scanner, then completely removed and put back into the scanner, and then positioned and scanned a 
second time. If necessary for patient c omfort, this evolution can be done immediately or with a short rest 
period so long as scanning is finished within the booked period of time. Longitudinal acquisitions will also 
be analyzed for longitudinal metabolite coefficients of variance and possible l ongitudinal metabolite 
changes.  
 
9.6 Definition of Evaluable Subjects, On Study, and End of Study  
For the initial monitoring of adverse events (see Section 15.4.2), evaluable patients will include the first 
[ADDRESS_34118] 3 vaccinations.  
For the final analys is of the primary objective (See section 15.4.2), evaluable patients will include all 
patients who received at least 6 vaccinations or experienced an unacceptable adverse event that was 
relate d to vaccine  (or vaccine + TMZ) .  
Once the patient signs ICF, that subject will be considered “on study .”  Rationale for taking patient off 
protocol treatment  will be  documented. End of study is defined as [ADDRESS_34119] vaccine for 
purposes of toxicity monitoring.  
9.7 Early Study Termination  
This study can be terminated at any time for any reason by [CONTACT_978] -sponsor . If this occurs, all subjects 
on study should be notified as soon as possible. Additional procedures and/or follow up should occur  in 
accordance with Section 12.5. Section 12.6 describes procedures and process for prematurely withdrawn 
patients.  
  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 26 
 CONFIDENTIAL  
 10 STUDY DRUG  
10.1 Names, Classification, and Mechanism of Action  
The name [CONTACT_34587]1M vaccine . The class of action is a biological .  
10.2 Packaging and Labeling  
Name  
[CONTACT_34588]: PEP IDH1M 
Lot #: Lot 001  
Caution New Drug Limited By [CONTACT_34541]  
10.3 Supply, Receipt, and Storage  
The PEP IDH1M will be manufactured under GMP conditions by [CONTACT_34542], Inc., and stored in the 
investigational pharmacy.  Montanide is supplied by [CONTACT_34543] 4OC in the investigational 
pharmacy.   
GM-CSF (LE[LOCATION_006]INE®; sargramostim) will be obtained from commercial supply, as a sterile, white, 
preservative- free powder lyophilized powder in a vial containing 250 mcg to be reconstitut ed in 0.5 mL of 
sterile water for injection.  
Store GM- CSF under refrigeration at 2- 8°C (36- 46°F). Vials must not be frozen.  
Lyophilized GM- CSF vials contain no antibacterial preservative, and therefore solutions prepared with 
Sterile Water for Injection,  USP should be administered as soon as possible, and within [ADDRESS_34120] any unused portion for 
administration more than 6 hours following reconstitution. Bacteriostatic Water for Injection, USP (0.9% 
benzyl alcohol) should NOT be used.  
Aseptic technique should be employed in the preparation of all GM- CSF solutions. To assure correct 
concentration following reconstitution, care should be exercised to eliminate any air bubbles from the needle 
hub of the syringe used to prepare the diluent. During reconstitution of lyophilized GM- CSF, the diluent 
should be directed at the side of the vial and the contents gently swirled to avoid foaming during dissolution.  
PEP IDH1M will be stored at -80OC, thawed,  and inspected visually for particulate matter and discoloration 
prior to administration. If particulate matter is present or the solution is discolored, the vial should not be 
used. Before use, the vial should be gently swirled to ensure uniform mixing of the contents. Avoid 
excessive or vigorous agitation; do not shake.  
Td is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single 
dose; substitute 1- time dose of Tdap for Td booster, then standardly  boost with Td every 10 years. Please 
refer to section 7.2  on the use of Td in this protocol . This study agent Td  (Tetanus diphtheria toxoid 
adsorbed) is supplied b y Duke Pharmacy  and stored at 4oC. 
10.[ADDRESS_34121] of care and according to package insert instructions 
(please see appendices  in Section 18) with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) I.M. 
into the deltoid muscle . In addition, vaccine site pre- conditioning will be performed as a single dose of Td 
toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered i.d. to the RIGHT  side of the 
groin one day  prior to the first vaccine.  
10.4.2  PEP IDH1M Vaccine with GM -CSF and Montanide ISA 51  
The PEPI[INVESTIGATOR_34484]1M vaccine and GM- CSF will be mixed with Montanide ISA 51 (shortened to  PEPI[INVESTIGATOR_34484]1M  
vaccine  for the other sections of this protocol) in the investigational pharmacy and will be delivered directly 
to the bedside under the supervision of the research nurse. Vaccines will be administered according to 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 27 
 CONFIDENTIAL  
 protocol . The patient’s name, Study ID, DOB, and MRN  will be double verified prior to vaccine  
administration.  
PEPI[INVESTIGATOR_34484]1M will be co -administered with GM- CSF and mixed 1:1 with Montanide ISA 51.  
Lyophilized GM -CSF should be reconstituted with Sterile Water for Injection, USP. Bacteriostatic Water 
for Injection, USP (0.9% benzyl alcohol) should NOT be used. During reconstitution, the diluent should be 
directed at t he side of the vial and the contents mixed by [CONTACT_34544]. 
Avoid excessive or vigorous agitation; do not shake.  
Each vial of lyophilized GM -CSF (250 mcg/vial) should be reconstituted with 0. 43 ml of Sterile Water 
for Injection, USP 0.35 ml of reconstituted GM- CSF will be withdrawn, under aseptic conditions, using a 
hypodermic needle and syringe.  
Each vial of PEP IDH1M  will be thawed at room temperature PEPI[INVESTIGATOR_34484]1M  should fully thawed within 0.5 
to 3 minutes, with no remaining visible frozen drug or particulate. The resultant solution of PEP IDH1M  (0. 
4 ml of 2 .0 mg/ml PEPI[INVESTIGATOR_34484]1M ) is a clear and colorless solution.  
The syringe with the previously withdrawn GM- CSF (0.35 ml volume containing 203 mcg GM- CSF), will 
be used to withdraw  0.35 mL of peptide.  The aqueous peptide/GM- CSF is mixed  1:1 with 0.7 mL of  
Montanide ISA 51 a ccording to the manufacturer’s instructions . One mL of the mixture will be administered 
by [CONTACT_34545] (in divided doses)  in the patient’s groin.  
After mixing, the PEPI[INVESTIGATOR_34484]1M/GM -CSF/Montanide mixture will contain approximately 500 mcg 
PEPI[INVESTIGATOR_34484]1M and 150 mcg GM- CSF in 1 mL of mixture.   
PEPI[INVESTIGATOR_34484]1M,  GM-CSF and Montanide ISA 51 contain no antibacterial preservative, and therefore 
solutions prepared with Sterile Water for Injection, USP should be administered as soon as possible. The peptide mixture can be stored for not more than 6 hours at 2- 8°C and for not more than 3 hours at  room 
temperature.  
Each PEP
IDH1M/GM-CSF/Montanide immunization should be administered i.d. near the groin, divided 
into 2- [ADDRESS_34122] be performed using an appropriate 
needle for intradermal administration.  
Following administration of the PEP IDH1M vaccine , the patient should be retained for obs ervation for a 
minimum of 30 minutes.  
10.5 Compliance and Accountability  
Upon receipt from the manufacture the PEP IDH1M and the GM- CSF/Montanide will be stored in the 
investigational pharmacy in a temperature controlled, locked access controlled storage unit. All drug 
transfers, receipts, and disposals are recorded in the Web- based drug accountability system . The vaccine  
will be signed out and dis tributed by [CONTACT_34546]. The Duke investigational pharmacy 
personnel use safe medication practices to reduce the risk of medication errors and adverse events when setting up study drug procedures . They are clearly labeled with the identi ty of the study drug and other 
control numbers .  
10.[ADDRESS_34123] ELIGIBILITY  
11.1 Inclusion Criteria  
1. Age ≥ 18 years . 
2. IDH1R132H expression in primary  tumor  
3. Clinical and /or radiographic , progressive and resectable Grade II glioma.  
4. Signed informed consent .  
5. For females of child- bearing potential, negative serum pregnancy test at screening (within 48 
hours prior to leukapheresis).  
Pro00054746: RESIST Study  
Version: [ADDRESS_34124] agree to practice adequate 
contraception.  
7. KPS of ≥ 70. 
8. CBC/differential with adequate bone marrow function as defined below within 2 weeks of enrollment:   
a) Absolute neutrophil count, ≥ 1500 cells/mm
3. 
b) Platelet count, ≥ 100,000 cells/mm3. 
c) Hemoglobin ≥ 10 g/dl. (Note: the use of transfusion or other intervention to achieve Hgb ≥ 
10 g/dl is acceptable.)  
9.  Adequate renal function as defined below within 2 weeks of enrollment:  
a) BUN ≤ 25 mg/dl.  
b) Creatinine ≤ 1.7 mg/dl.  
10.  Adequate hepatic function as defined below within 2 weeks of enrollm ent: 
a) Bilirubin ≤ 2.0 mg/dl. 
b) ALT ≤ 3 x normal range.  
c) AST ≤ 3 x normal range.  
11.2 Exclusion Criteria  
1. Prior invasive malignancy (except for non- melanomatous skin cancer) unless disease free for ≥ 3 
years. (For example, carcinoma in situ of the breast, oral cavity , and cervix are all permissible.)  
2. Metastases detected below the tentorium or beyond the cranial vault . 
3. Severe, active co- morbidity, defined as follows:  
a. Unstable angina and/or congestive heart failure requiring hospi[INVESTIGATOR_059].  
b. Myocardial infarction within  the last 6 months.  
c. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol . The need to exclude 
patients with AIDS from this protocol is necessary because t reatments involved in this 
protocol may be significantly immunosuppressive.  
d. Major medical illnesses or psychiatric impairments that in the investigator's opi[INVESTIGATOR_34493].  
4. Pregnant or lactating women, due to possible adverse effects on the developi[INVESTIGATOR_34494].  
5. Prior allergic reaction to temozolomide.  
6. Patients treated on any other therapeutic clinical protocols within [ADDRESS_34125] -derived products, or any component of 
Leukine®.  
8. Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine.  
9. Unable to undergo MRI imaging.  
[ADDRESS_34126] include pathology report from initial diagnosis to  confirm IDH1
+ 
WHO Grade II glioma diagnosis  with MRI showing progressive lesion  located i n resectable areas . Once 
consent is obtained, subjects will receive  Td booster immunization I.M. Study-mandated leukapheresis is 
scheduled to occur followed by  [CONTACT_34547] i.d. pre-conditioning scheduled 48 hours or less . Vaccine #[ADDRESS_34127] blood samples taken for the following tests as required by [CONTACT_34548]: 
CBC w/diff, CMP, ionized Calcium, and β -HCG (for females of child- bearing potential). Total estimated 
blood volume required for these evaluations is 12- 15 mLs. For patients without sufficient venous access for 
leukapheresis, a temporary central intravenous catheter may be inserted. To prevent the development of 
hypocalcemi a from the citrate used for leukapheresis, all patients will be instructed to take oral Tums, 2 
Pro00054746: RESIST Study  
Version: [ADDRESS_34128] protocols under the 
direction of apheresis attending physician.  An aliquot of 107 PBMCs will be collected from this leukapheresis 
and sent to UNC Center for AIDS Research Virology, Immunology, & Microbiology Core Laboratory  at [ADDRESS_34129], Genome Sciences Building, Room 2158, Chapel Hill, NC [ZIP_CODE] -7291. This blood sample 
will be sent to UNC for HLA assessment and ana lysis (please see Section 9.3 for rationale) . 
Subsequent vaccines will be given on day 15 ±3 days (vaccine #2) and day 29 ±3 days  (vaccine #3) . 
Seven to [ADDRESS_34130] of 
care and monthly vaccines.   For higher grade gliomas undergoing RT, vaccine #4 will be given during SOC 
clinic visit prior to initiating RT,  and vaccine # 5 will be given 4 weeks later (± 1 week) during RT.  Vaccine 
#[ADDRESS_34131] -RT TMZ, if MRI 
stable.  Then, subjects in this treatment group will receive vaccines monthly on day 2 2 (+2 days ) with post -
RT cycles of TMZ to a maximum of 15 vaccines .     
If possible, t he provider will take a photo of the injection site at the pre- op appointment seven to twelve 
days after vaccine #[ADDRESS_34132]’s  reaction to the vaccine.  The provider may take additional  
pi[INVESTIGATOR_34495] . There will be no identifiers on the photographs. The photographs will be taken by [CONTACT_423]’s 
provider and may be uploaded to their  electronic medical record or kept in a separate electronic or paper 
research file. The photographs will be uploaded to the electronic medical record by [CONTACT_34549]. These applications allow for the photograph to be 
uploaded directly to  the electronic medical record without the photographs being stored on the dev ice taking 
the pi[INVESTIGATOR_1103].   A ruler will be included in the photo to allow measurement of the size of the injection site 
reaction.   
To demonstrate quantitative repeatable measures of 2HG change in IDH1+ gliomas, patients will be 
scanned on the CAMRD MR scanner using a an MRS protocol. We will acquire MRS data at up to 5 time 
points: baseline (after consent and before PEP IDH1M vaccine #1) and up to 4 times prior to surgery  (please 
refer to Section 9.5 for more detail) . 
 
IDH1 R132H biomarker component of the protocol  and immune monitoring : 
a) Study of tumor -specific circulating nucleic acid from plasma of patients with gliomas with 
IDH1 R132H:  
We p lan to isolate circulating nucleic acids from the plasma of patients affected by [CONTACT_34550] -specific circulating DNA containing the c.395G>A (R132H) mutation. We will follow the 
protocol  as described by [CONTACT_34551], et al ., Neurology 201283 for plasma collection. Twenty  mLs of blood will 
be the appropriate amount for our analyses (should yield ~10mL of plasma).  At the same time,  we will 
collect peripheral blood for immune monitoring. Ideally, we would like to have these blood samples 
collected:  
- (1) Prior to initiating vaccine therapy  at the leukapheresis visit , 
- (2) Prior to surgical resection  at the pre- op screening visit , 
- (3) Prior to first cycle  of TMZ at the SOC clinic visit  (confirmed Grade IIs), or prior to RT/TMZ at 
SOC clinic visit (higher Grade Gliomas) , 
- (4) Vaccine #6  
- (5) End of Treatment ( follow -up visit 1 month after v accine #15).  If a subject decides to stop 
participat ing in the study prior to vaccine #15, blood will be obtained at that time (if possible) .  If a 
subject progresses prior to vaccine #15, blood will be obtained at that time (if possible).  
b) Study of 2 -Hydroxyglutarate levels in patients with gliomas with ID H1 R132H:  
The second approach to be used will be a mass spectrometry -based approach for detection of 2-
hydroxyglutarate (2- HG), a metabolite specifically produced by [CONTACT_34552]1 c.395G>A (R132H) 
mutation. This metabolite can be sensitively detected by [CONTACT_34553]1 R132H -containing gliomas as well as in the plasma of other solid tumors 
containing the same mutation (cholangiocarcinoma, subsets of breast carcinoma). A small portion of the 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 30 
 CONFIDENTIAL  
 previously m entioned isolated plasma will be used for a LC -MS/MS based approach for sensitive detection 
of circulating 2- HG levels .  
Tumor tissue –  we are planning to obtain a snap- frozen tumor tissue sample  after the surgical resection  
for possible presence of IDH 1 mutation and gene up- regulation.    
 
Tumor  Sampling Analyses:  
At the time of surgical resection, excess tumor tissue will be obtained through the Duke B iorepository, 
and IHC analyses will be performed to assess immunologic infiltrate which will be identified  by [CONTACT_34554].   
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 31 
 CONFIDENTIAL  
 Table 2. Screening and On -Study Tests and Procedures  
 
 
 
  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 32 
 CONFIDENTIAL  
  Screening  Leukapheresis2 
 One d ay 
prior to  
vaccine 
#1 Vaccine 
#1 Vaccine  
#2 Vaccine 
#[ADDRESS_34133] -
Surgery  
Pre TMZ 
visit9 Radiation 
Therapy 
and TMZ8 TMZ 
Cycles  
1-12 9,10 End of 
Treatment  
(1 month 
after 
Vaccine 
#15)  Progression  
*followed for 
survival  
ICF X             
Medical 
History/ 
Baseline 
symptoms  X  X           
Tumor 
pathology  X       X     X  
If possible  
Blood for 
Immune  
monitoring/Biomarker testing
5   X 
3 red      X 
17 
yellow,  
1 red  X 
17 
yellow,  
1 red  X 
17 yellow,  
1 red  
 
At vaccine 
#6 X 
17 
yellow, 1 
red 
 
At 
vaccine 
#6 X 
17 yellow,  
1 red  
CBC/diff and 
CMP3  X X     X  X X8 X X  
Beta HCG 
(for WOCBP)   X 
     X 
  X 
     
Ionized Ca   X            
TD Booster4 X             
MRI1 X 
      X 
 X   X 
every 2 -3 
months    
MRS 2HG6  X  X X X X       
Pre-
conditioning 
TD11    X 
           
TMZ 50 -100 
mg/m2 21 of 
28 days x  12 
cycles            X   
Radiation 
Therapy8          X8    
TMZ 
75mg/m2/day 
for 42 days8          X8    
Vaccine10 
Total of 15 
vaccines     X 
 X 
 X 
    X10 
 X10 
   
Physical 
Exam,  
Neuro exam, 
KPS X  X  X X   X X8 X X  
Con Meds  X X X X X X X X X X8 X X  
AE/SAE 
collection  X X X X X X X X X X8 X X  
Photo of 
injection site 
(Optional to 
subject)[ADDRESS_34134] be performed within 10 weeks (+/ - 4 weeks)  of signing consent. MRI or contrasted CT, every 
10 weeks  (+/- 4 weeks ) per PRTBTC standard of care (may be adjusted by [CONTACT_34555]- oncologist).  MRI will be done pre - and post -surgery per 
surgeon discretion and standard of care.  
[ADDRESS_34135] blood samples taken for the following tests 
as required by [CONTACT_34548]: CBC, CMP, ionized Calcium, and β -HCG (for females of child -bearing potential). Total estimated blood volume 
required for these evaluations is 12- 15 mLs. An aliquot of PBMCs from this pheresis will be sent to UNC for HLA analysis.  
3 CMP and CBC (with differential) to confirm eligibility, and as per standard of care prior to and following surgery, and durin g monthly cycles of TMZ. CBC 
and CMP will be repeated along with a physical examination [ADDRESS_34136] vaccine to assess for delayed toxicity to v accine therapy.  
4 Td booster will be given I.M. into the deltoid muscle after consent on all subjects.  
5 Immune monitoring and  Biomarker testing will be drawn before initiation of vaccine therapy (at leukapheresis visit), prior to surgical resection, p rior to 
RT/TMZ and vaccine #4 or cycles of TMZ (depending on tumor pathology), at vaccine # 6, and at end of treatment ( at the follow-up visit 1 month after 
vaccine #15, at the time come off study  treatment , or at progression, whichever comes first ).  Blood for i mmune monitoring and Biomarker testing will be 
placed in 14 yellow containing ACD and 1 red vacutainer tube for a total of 90 mLs delivered to the BTIP lab for processing (3  red top s will be drawn 
with leukapheresis  instead) . Genomic proteomic analyses will include tumor sample at surgery and 20 mLs of blood (3 yellow ACD tubes) drawn at 
leukapheresis visit, at the pre- op scr eening visit prior to surgery, and depending on tumor pathology at the SOC clinic visit prior to starting either RT/TMZ 
(and receiving the 4th vaccine) or the 1st cycle of TMZ , at vaccine #6,  and at end of t reatment ( at the follow- up visit 1 month after vaccine #15, at the time 
come off study treatment, or at progression, whichever comes first ). 
6 To demonstrate quantitative repeatable measures of metabolism change in IDH1+ gliomas via a standardized MRS protocol, patients will be scanned 
on the research MR scanner at up to [ADDRESS_34137]: baseline (after consent and before PEP IDH1M vaccine #1 ), and up to 4 times prior to 
surgery.   Up to 5 MRS scans can be scheduled between consent and surgery, but they are not required to be scheduled on the same day as PEP IDH1M 
vaccines #1-3. 
Pro00054746: RESIST Study  
Version: [ADDRESS_34138].  
10 For higher grade gliomas undergoing RT, vaccine #4 will be given during SOC  clinic visit prior to initiating RT, and vaccine # 5 will be given 4 weeks 
later (± 1 week) during RT.  Vaccine #[ADDRESS_34139] -RT TMZ, if MRI stable.  
Then, subjects in this treat ment group will receive vaccines monthly on day 22 (+2 days) with post -RT cycles of TMZ to a maximum of 15 vaccines.  
Subjects with a stable grade glioma at time of surgery will receive vaccines #4 -15 monthly on day 22 (+2 days) of TMZ cycles.  
11Tetanus p re-conditioning will be done i.d. into the right groin one day  before vaccine #1, as described in protocol.  
[ADDRESS_34140] transitioned to a 
higher grade brain tumor, v accines will then continue monthly along with adjuvant cycles of TMZ on day 22  
(+ 2 days)  for a maximum of [ADDRESS_34141] vaccine for blood work (CBC and CMP) and clinical assessment to 
monitor for delayed toxicity.  
12.[ADDRESS_34142] ed 
following progression (whichever comes first) , the treatment phase of the study will be completed.  
12.4 Follow -up Period  
Once the treatment phase has been completed, patients will be followed for OS , PFS, and subsequent 
therapi[INVESTIGATOR_34496] . For recording of subsequent therapi[INVESTIGATOR_014], the type, agent, 
and duration  of therapy(ies) that the subject receives will be recorded .  
12.[ADDRESS_34143]  receives the final vaccine, the investigational vaccine treatment  will be considered 
as complete and collected data will be analyzed for safety and toxicity.    
Subjec ts will be followed for OS , PFS, and subsequent therapi[INVESTIGATOR_34497] d ata will be updated.  Furthermore, 
in case of disease progression, every attempt will be made to obtain tissue  for immune  monitoring (if biopsy 
or resection  performed) .  
12.[ADDRESS_34144](s)  
12.6.[ADDRESS_34145] from 
the study at any time based on his/her discretion. Reasons for PI -initiated withdrawal may include, but are 
not limited to the following:  
• Progressive disease as documented by [CONTACT_34556]-op immunotherapy  or post -RT immunotherapy (for those who’ve transitioned 
to a higher grade at time of surgery)  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 34 
 CONFIDENTIAL  
 • Development of unacceptable toxicity , as defined in section 9.1.1  
• Pregnancy  
• Need for corticosteroids > 4mg /day at time of 1st vaccine  
• Upon request of the subject  
• If, in the investigator’s medical judgment, further participation would be injurious to the 
subject’s health or wellbeing 
• Development of intolerable symptoms  
• Protocol deviation  
• Administrative reasons, such as a major violation of the clinical trial protocol  
• Non- compliance of the subject  
• Clinical decline or inability  to be weaned off steroids following surgery  
• Failure to undergo surgery following the 3rd vaccine  
• Failure to tolerate TMZ therapy.  
12.6.[ADDRESS_34146] to follow up.  Subjects 
that voluntarily withdraw will be asked permission to follow for survival.  Subjects that are withdrawn prior to  
vaccine  treatment for any of the aforementioned reasons will be considered eligibility failures and thus will 
not be followed for survival.   
12.6.3  Replacement of Early  Withdrawal (s) 
Subjects who voluntarily withdraw prematur ely (i.e. before receiving the first 3 vaccinations) or who are 
withdrawn by [CONTACT_978] [INVESTIGATOR_34498] a n unacceptable 
toxicity as defined in section 9.1.[ADDRESS_34147] 
and/or family at the screening visit and reviewed at each study visit . This data may include the following:  
• All past medical and surgical history  
• Current medications   
• Changes in physical or neurologic symptoms  
• Any adverse events   
12.7.2  Physical Exam  
Vital signs and physical and neurologic examinations will be assessed and recorded along with a KPS 
score prior to enrollment , at the Td pre- conditioning i.d. visit,  and at each vaccine  visit (with the exception 
of vaccine #1 where only vital signs will be assessed) . 
 
12.7.[ADDRESS_34148]’s antihistamines to be held before and following vaccine 
administrations . 
Pro00054746: RESIST Study  
Version: [ADDRESS_34149] tumor responses, any evidence of tumor response will be determined according 
to the Duke PRTBTC SOP ( available upon request ). RANO criteria82 will be used for overall assessment of 
tumor response and pseudoprogres sion versus progression. Progression by [CONTACT_34557]:  1) New contrast -enhancing lesion outside of radiation field on decreasing, stable, or 
increasing doses of corticosteroids; 2) ≥ 25% increase in the sum of the products of perpendicular diameters 
between the first post radiotherapy scan, or a subsequent scan with smaller tumor size, and the scan at 12 weeks or later on stable or increasing doses of corticosteroids; 3) Clinical deterioration not attributable to 
concurrent m edication or comorbid conditions is sufficient to declare progression on current treatment but 
not for entry onto a clinical trial for recurrence; 4) For patients receiving antiangiogenic therapy,  significant 
increase in T2/FLAIR non- enhancing lesion may a lso be considered progressive disease. The increased 
T2/FLAIR must have occurred with the patient on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy  and not be a result of comorbid events ( e.g., 
effects of  radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or 
other treatment effects ). Since some of these subjects will not be undergoing radiation therapy, and the 
possibility to exhibit pseudoprogression is likely due to inflammation from immune response at the site of 
the tumor , RANO criteria will be used to monitor for pseudoprogression versus progression. If 
pseudoprogression is suspected, the subject will continue with vaccine therapy for a mi nimum of 2- [ADDRESS_34150] remains clinically and radiographically stable compared to the MRI showing suspected pseudoprogression  as long as the following criteria are met: 1) the subject experiences 
investigator -assessed clinical benefit (i.e., no new clinical symptoms contributed to disease progression) 
and 2) the subject is tolerating the study treatment (i.e., no expected toxicities higher than grade 3 or 
unexpected toxicities) .  If the subject continues to do well beyond the 3 months, they will continue on study 
as planned.  
12.8 Risk/Benefit Assessment  
12.8.[ADDRESS_34151]’s brain cancer . Because 
this procedure is experimental, it cannot be guaranteed that subjects will receive any benefit as a result 
of participating in this research study . The information collected in this research may help scientists 
better understand the mechanisms involved in the immune system’s ability to fight cancer . If such an 
understanding comes from this research, then it may benefit society by [CONTACT_34558].  
12.8.[ADDRESS_34152] 
extreme circumstances, death. In addition, if the immune system becomes overly activated, potential 
discomforts may include pain, r edness and swelling at the injection site.  
Injection Site  
EMLA ® cream, or equivalent topi[INVESTIGATOR_34499], can be offered to subjects who experience local 
pain at the injection site.  
Cerebral Edema 
Cerebral edema may be secondary to the disease process itself, the surgical procedure,  radiation 
therapy,  necrosis from previous radiation, or inflammation due to immune infiltration of the brain or 
destruction of tumor cells . Symptoms may include, but are not limited to, severe headache, confusion, 
Pro00054746: RESIST Study  
Version: [ADDRESS_34153] extreme situation, this may lead to systemic bacterial/fungal sepsis and 
possibly death. The probability of this risk is relatively low, given the small injection volume (1 mL 
divided between >2 intradermal locations) and the fact that the peptides will be strictly tested for sterility 
prior to each injection . The risk of infection due to potential contamination of the peptides in the 
laboratory will  be minimized by [CONTACT_34559]. All cell cultures will be handled 
under sterile conditions in a core tissue culture facility dedicated to the processing of human cells . Prior 
to injection into patients, peptides must pass sterilit y tests in thiglycolate broth, tryptic soy blood agar, 
and inhibitory Sabouraud agar . Following injections, patients will be monitored throughout the course 
of the study for any signs and symptoms of infection. There have been no infections to date in the recent VICTORI (IRB #3108- 05-9R4) or ACTIVATE (IRB #5421- 05-1R1) clinical trials testing similar 
approaches in a similar patient population. If an active infection is suspected, patients will be cultured 
and treated with appropriate antibiotics.  
Delayed Autoimmune Diseases  
It is possible that delayed autoimmune disease(s) may develop as a result of injection with PEP IDH1M 
vaccine . This means that the immune system may be stimulated to attack natural tissue in the body . 
Animal studies have reported the devel opment of autoimmunity in the context of vaccination and 
recovery from lymphopenia. However, our current experience with peptide vaccination in glioma 
patients has not demonstrated evidence of autoimmunity in treated patients . Furthermore, the doses of 
TMZ used in this study for induction of lymphopenia are standard doses administered to patients with 
gliomas . It therefore, is unknown what the risk of delayed autoimmune disease is for this study.  
Phlebotomy  
Drawing blood or inserting an intravenous catheter  into an arm vein may result in bruising or 
swelling in the area of the insertion, bleeding at the site of the needle puncture, light headedness, 
fainting and very rarely, local infection, which may be severe. These risks are reduced by [CONTACT_34560] a qualified physician, nurse or phlebotomist (a professional trained to draw blood).  
Leukapheresis  
As with any donation of blood, a variety of minor reactions may occur with leukapharesis, which 
include fainting, dizziness, or nausea.  Uncommon but serious complications may also result, which 
include bleeding, infection, an adverse reaction to the anticoagulant or replacement fluids, hypocalcemia, hypotension, shock, convulsions, air emboli, heart failure, or the inability to transfuse blood back into the patient . These risks are reduced by [CONTACT_34561] a specialized clinical hemapheresis unit . Patients will be carefully monitored 
throughout the procedure by [CONTACT_34562] . Calcium gluconate (2 gm) will be given 
to minimize the risks of hypocalcemia, fluid supplementation will be given to minimize hypotension.  
MRI 
The risks and/or discomforts associated with the performance of MRI include the anxiety produced 
from b eing in a tight, enclosed space (claustrophobia) . In addition, the machine operates using a large 
and powerful magnet . The magnetism of the machine attracts certain metals: therefore, people with 
these metals in their bodies (specifically pacemakers, infus ion pumps, metal aneurysm clips, metal 
prostheses, joints, rods or plates) will be excluded from the study  if they are unable to undergo MRI 
imaging. Patients will also be checked to make sure that they do not bring any metal objects into the MRI facility . Dental fillings are less affected by [CONTACT_34563]. It will be asked that patients let the physicians conducting this study know of any metal in 
their bodies other than dental fillings .  
Allergic Reactions to Contrast Agents  
Pro00054746: RESIST Study  
Version: [ADDRESS_34154] agents will be 
excluded from the study . Patients with mild allergies (i.e., rash only) will be pretreated with Tylenol and 
Benadryl prior to injection of the contrast agent . 
Radiation Therapy  
Early side effects of radiation include hair loss, scalp redness, inflammation of the ear canals, and 
fatigue. In a few patients, radiation contributes to headaches or nausea. Rarely, tumors may swell 
during radiation causing neurologic al symptoms such as weakness on one side, visual loss, or changes 
in mental function. There is a small chance of long- term effects from radiation, occurring months or 
years after completion. These may include worsening of mental function, hearing, vision, strength and 
coordination. Rarely, radiation may cause the development of benign or malignant tumors around the 
brain or skull. It is unknown whether temozolomide increases the risk of any of the early or late side 
effects of radiation.  
Temozolomide  
TMZ has been well tolerated by [CONTACT_34564]. Other, less likely, potential toxicities include nausea and vomiting, constipation, 
headache, alopecia, rash, burning sensation of skin, esophagi tis, pain, diarrhea, lethargy, 
hepatotoxicity, anorexia, fatigue and hyperglycemia. Hypersensitivity reactions have not yet been noted 
with TMZ . As in the case with many anti -cancer drugs, TMZ may be carcinogenic . Rats given TMZ 
have developed breast cancer . The significance of this finding for human is not presently known. TMZ 
therapy will be followed but given as standard of care. If toxicities occur, the Principle investigator and 
primary physician will titrate therapy based on standard clinical guidelines as outlined above.  
GM-CSF 
Injection of GM- CSF may increase the risk of infection, lower platelets, or cause fluid retention. 
GM-CSF also may result in an allergic reaction, which could include redness and swelling at the 
injection site, itching, hives, flushing, syncope, low blood pressure, difficulty breathing, or in the most 
extreme circumstances, death. In addition, if the immune system becomes overly activated, potential 
discomforts may include pain, redness and swelling at the injection site.  
Montanide ISA [ADDRESS_34155] a causal relationship with this treatment . For this protocol, the definition of AE also 
includes worsening of any pre- existing medical condition. An AE can therefore be any unfavorable and 
unintended or worsening s ign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of the PEP IDH1M and GM- CSF, whether or not related to use of the vaccine . 
Abnormal laboratory findings without clinical significance (based on the PI’s j udgment) should not be 
Pro00054746: RESIST Study  
Version: [ADDRESS_34156] signs the informed consent form through the End of Treatment  visit (as 
defined in Sections  12.3, 12.5 and 12.6), all AEs must be recorded in the subject medical record and 
electronic adverse events case report form.  
AEs will be assessed according to the CTCAE version 4.0. If CTCAE grading does not  exist for an AE, 
the severity of the AE will be graded as mild (1), moderate (2), severe  (3), life-threaten ing (4), or fatal (5).  
Attribution of AEs will be indicated as follows:  
• Definite : The AE is clearly related to the study drug  
• Probably : The AE is likely related to the study drug  
• Possible : The AE may be related to the study drug  
• Unlikely : The AE is doubtfully related to the study drug  
• Unrelated : The AE is clearly NOT related to the study drug  
13.1.1  Reporting of AEs  
A summary of all adverse events (not just those considered related to the study drug) will be kept which 
will categorize the event by [CONTACT_34565], relationship to treatment, its grade of severity, and resolution. 
The PI [INVESTIGATOR_34500] a monthly basis . If any such trends are identified, depending on their severity and 
frequency, a protocol amendment will be considered.  
13.2 Serious Adverse Events  
An AE is considered “serious” if in the opi[INVESTIGATOR_34501] : 
• Death,  
• A life-threatening adverse event,  
• A congenital anomaly or birth defect , 
• Inpatient hospi[INVESTIGATOR_1081],  
• A persistent or significant incapacity or substantial disruption in the ability  to conduct normal life 
functions.  
Important medical events that may not result in death, be life- threatening, or require hospi[INVESTIGATOR_34502], based upon appropriate medical judgement, the event may jeopardize the subject and may  require medical or surgical intervention to prevent one of the outcomes listed in this 
definition. Furthermore, an important medical event that is not otherwise an SAE may be considered serious if the event may jeopardize the subject and may require medic al or surgical intervention to prevent one of 
the outcomes listed in this definition.  
13.2.[ADDRESS_34157]. Katherine Peters  (Pager: 919 -970-7591) or her 
designee (919- 684-8111) and to the FDA . Fatal or life- threatening, unexpected adverse events will be 
reported to the FDA by [CONTACT_756], facsimile, or in writing as soon as possible, but no later than [ADDRESS_34158] knowledge by [CONTACT_456].  
All adverse events that are considered serious, unanticipated, and related or possibly related to the 
research (as defined by 21CRF312.32[a]) will be reported to the FDA and the Duke University Medical 
Center IRB using the appropriate SAE report form . At th e time of the annual progress report to the FDA 
and the Duke University Medical Center IRB, a summary of the overall toxicity experience will be provided.  
13.[ADDRESS_34159] 
an independent DSMB. The primary focus of the Safety Oversight Committee is review of safety data, 
Pro00054746: RESIST Study  
Version: [ADDRESS_34160] safety or efficacy. Annual safety reviews includes but 
may not be limited to review of safety data, enrollment status, stoppi[INVESTIGATOR_12596], accrual, toxicities, 
reference literature, and interim anal yses as provided by [CONTACT_456] -investigator . The Safety Oversight 
Committee in concert with the DCI Monitoring Team (see Section 14.1 for Monitoring Team descripti on) 
oversees the conduct of DUHS cancer -related, sponsor -investigator therapeutic intervention and 
prevention intervention studies that do not have an external monitoring plan, ensuring subject safety and 
that the protocol is conducted, recorded and report ed in accordance with the protocol, SOPs, GCP, and 
applicable regulatory requirements.  
[ADDRESS_34161] 
is enrolled, followed by [CONTACT_12636] 1– 3 subjects until the study is closed to enrollment and subjects 
are no longer receiving study interventions that are more than minimal risk .  
Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of 
serious and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, the DCI Cancer Protocol Committee, the Safety Oversight Committee, the sponsor, the 
Principal Investigator, or the IRB . All study documents must be made available upon request to the DCI 
Monitoring Team and other authorized regulatory authorities, including but not limited to the National Institute of Health, National Canc er Institute, and the FDA . Every reasonable effort will be made to maintain 
confidentiality during study monitoring.  
14.2 Audits  
The Duke School of Medicine Office of Audits, Risk, and Compliance (OARC)  office may conduct audits 
to evaluate compliance with the protocol and the principles of GCP . The PI [INVESTIGATOR_34503](s) direct access to all relevant documents and to allocate his/her time and the time of the study team to the OARC  audito r(s) in order to discuss findings and any relevant issues.  
OARC  audits are designed to protect the rights and well -being of human research subjects. OARC  
audits may be routine or directed (for cause). Routine audits are selected based upon risk metrics generally 
geared towards high subject enrollment, studies with limited oversight or monitoring, Investigator initiated 
Investigational Drugs or Devices, federally -funded studies, high degree of risk (based upon adverse events, 
type of study, or vulnerable populations), Phase I studies, or studies that involve Medicare populations. 
Directed audits occur at the directive of the IRB or an authorized Institutional Official.  
OARC  audits examine research studies/clinical trials methodology, processes and systems to assess 
whether the research is conducted according to the protocol approved by [CONTACT_12638]. The primary 
purpose of the audit/review is to verify that the standards for safety of human subjects in clinical trials and 
the quality of data produced by [CONTACT_34566]. The audit/review will serve as a quality 
assurance measure, internal to the institution. Additional goals of such audits are to detect both random and systemic errors occurring during the conduct of clinical research and to em phasize “best practices” in 
the research/clinical trials environment.  
14.3 Data Management and Processing  
14.3.1  Study Documentation  
Study documentation includes but is not limited to source documents, case report forms, monitoring 
logs, appointment schedules, study t eam correspondence with sponsors or regulatory bodies/committees, 
and regulatory documents that can be found in the DCI -mandated “Regulatory Binder ,” which includes but 
is not limited to signed protocol and amendments, approved and signed informed consent forms, FDA Form 
1572, CAP and CLIA laboratory certifications, and clinical supplies receipts and distribution records.  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 40 
 CONFIDENTIAL  
 Source documents are original records that contain source data, which is all information in original 
records of clinical findings, observ ations, or other activities in a clinical trial necessary for the reconstruction 
and evaluation of the trial . Source documents include but are not limited to hospi[INVESTIGATOR_1097], clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or ev aluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_27602], microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject 
files, and records kept at the pharmacy, at the laboratories and at medico- technical departments involved 
in the clinical trial . When possible, the original record should be retained as the source document . However, 
a photocopy is acceptable provided that it  is a clear, legible, and an exact duplication of the original 
document.  
14.3.[ADDRESS_34162]’s medical records will be the primary source document for the study. Source documents 
include all information in original records and certified copi[INVESTIGATOR_34504], observations, or other activities in a clinical investigation used for reconstructing and evaluating the 
investigation
1. Source document ations may also include paper eligibility checklists, data flowsheets, patient 
reported outcomes and other paper documents. The PI, study coordinator, study research nurse, data management team and all associated study key personnel, are permitted to make entries, changes, or 
corrections in the source documents or database per the st udy delegation of authority log.  
Errors on the source documents will be crossed out with a single line, and this line will not obscure the 
original entry. Changes or corrections will be dated, signed, initialed, and explained (if necessary). 
Database changes will be tracked via electronic trail automatically . 
14.3.3  Data Management and Data Verification  
The DCI I T Shared Resource has developed  Title 21 CFR Part 11 compliant databases for cancer 
clinical trials. DCI IT  has extensive expertise in database quality as surance, data standards, and use of 
caBIG tools to support cancer researchers.  
Data queries  will be generated automatically by [CONTACT_1624] . These data queries signify  the 
presence of data inconsistencies. The study and data management team  will cross -reference the data to 
verify accuracy. Missing or implausible data will be highlighted for the PI [INVESTIGATOR_12598] (i.e. confirmation of data, correction of data, completion or confirmation that data is not available, etc.).  
The database wil l be reviewed and discussed prior to database closure, and will be closed only after 
resolution of all remaining queries . 
14.3.4  Coding of Adverse Events  
All adverse events  will be coded using CTC AE (version 4.0) .  
14.3.5  Study Closure  
Following completion of the studies, the PI [INVESTIGATOR_12599]:  
• Data clarification and/or resolution  
• Accounting, reconciliation, and destruction/return of used and unused study drugs  
• Review of site study records for completeness  
• Shipment of all remaining laboratory samples to the designated laboratories  
                                                      
1 In 21 CFR 312.62(b), reference is made to records that are part of case histories as “supporting data”; 
the ICH guidance for industry E6 Good Clinical Practice: Consolidated Guidance (the ICH E6 guidance) 
(available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm  
or http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm )  uses 
the term “source data/documents.” For the purpose of this guidance, these terms describe the same information and have been used interchangeably.  
Pro00054746: RESIST Study  
Version: [ADDRESS_34163] to the availability of data, a ll patients who receive any protocol treatment will be included in 
analyses addressing secondary objectives.  Statistical analyses for the primary objective will exclude 
patients who terminate protocol treatment prematurely (i.e. less than 6 vaccinations) without a n 
unacceptable toxicity . 
15.2 Patient Demographics and Other Baseline Characteristics  
Summaries of clinical a nd socio- demographic characteristics will be generated for all patients who 
receive vaccine treatment.  Categorical descriptors will be summarized using frequency distributions; 
whereas, interval variables will be summarized using percentiles, as well as means and standard 
deviations.  
15.3 Treatments  
A frequency distribution will be generated for the number of v accines received by [CONTACT_1962] . 
15.4 Primary Objective  
To assess the safety of the PEP IDH1M vaccine alone and in combination with adjuvant TMZ  and/or RT  
in adult patients with progressive, resectable WHO Grade II gliomas  that are confirmed Grade II or transition 
to a higher grade glioma at the time of surgery . 
15.4.[ADDRESS_34164] possibly attributed to the vaccine (or vaccine + TMZ  and/or RT ) 
that does not resolve to baseline within [ADDRESS_34165] 6 vaccines ([ADDRESS_34166] -surgery) . Less than 20% of patients are expected to drop out 
between enrollment and the 6th vaccin ation.  
Initial Study Monitoring For Adverse Events : Initially [ADDRESS_34167] -surgery treatment with TMZ and IDH1 vaccine . If 2 or less of these subjects 
experience an unacceptable toxicity , accrual will continue. Otherwise, modifications of the protocol will be 
considered before accruing additional subjects .  If a patient who has not experienced an  unacceptable 
toxicity  does not complete 3 vaccinations, that patient will be replaced for initial study monitoring.  
Overall Adverse Event Monitoring:  Rigorous monitoring of long-  and short -term toxicities in a manner 
similar to that found in many phase I dose- escalatio n studies would require accrual suspension between 
stages of patient accrual while relevant data matures . After the initial [ADDRESS_34168] 6 subjects, aggregate summaries of 
adverse experiences will be generated and reviewed by [CONTACT_34567] 6- 12 months.   The following 
are considered adequate documentation of review:  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 42 
 CONFIDENTIAL  
 • PI [INVESTIGATOR_34505] 6 months  for the 
DSMBplus meeting.   
• PI [INVESTIGATOR_34506].  As described 
in Section 13.1.1, the PI [INVESTIGATOR_34507] a 
monthly basis.    
Tabulated below are the conditions under which accrual will be temporarily suspended and data 
carefully reviewed to determine the appropriate action, including permanent study termination, continuation with patient accrual after appropriate amendment, or  continuation with patient accrual with no modification 
of the protocol  (Table 3). Accrual will also be suspended whenever a death occurs that is possibly, probably, 
or definitely related to treatment  with vaccine alone or vaccine and TMZ . 
Table 3. Conditions under W hich Accrual will be Suspended  
Number of 
patients accrued  Number of patients 
with unacceptable 
toxicity  requiring 
accrual suspension  
6-7 ≥3 
8-10 ≥4 
11-14 ≥5 
>14 ≥[ADDRESS_34169] not been adjusted for differential length of follow -up of accrued patients . The 
probability of accrual suspension as a function of the true unacceptable toxicity rate is tabulated below 
based upon simulation studies  (Table 4). These statistics were generated assuming toxicity outcome was 
known at the time of accrual, and ignored issues such as time to toxicity, accrual rate, and length of follow -
up. 
Table 4. Probability of Accrual Suspension as a F unction of the T rue Unacceptable Toxicity Rate 
Underlying 
unacceptable 
toxicity  rate Probability 
of accrual 
suspension  Expected # 
of Patients  
0.[ADDRESS_34170] -surgery are expected. Yung84 
reports that 18% of patients treated with TMZ alone experienced a grade 3 or 4 adverse event . Assuming 
vaccine does not increase the chances of unacceptable toxicity  and a n unacceptable toxicity  rate of 18% 
with TMZ, the probability of study suspension due to excessive unacceptable toxicity  is 0.21 . If the chances 
of unacceptable toxicity  increase the overall true unacceptable toxicity  rate, then the chances of study 
suspension due to excessive unacceptable toxicity increases to 0.80 with an underlying unacceptable 
toxicity  rate of 35%.  
Any patient who discontinues vaccination prior to the receipt of [ADDRESS_34171] transformed from 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 43 
 CONFIDENTIAL  
 Grade II to a higher grade will receive TMZ and radiation therapy  per standar d of care and monthly vaccines  
and will be included in the final analysis of the primary objective.   
15.4.3  Handling of missing values, censoring, and discontinuations  
If a patient does not receive any vaccine treatment, they will be excluded from all analyses .  
15.5 Secondary Objective  
An important secondary goal of this study is t o assess the immunogenicity of the PEP IDH1M vaccine alone 
and in combination with  adjuvant TMZ using ELISpot . Levels of immune response will be examined after 3 
vaccinations ( i.e., pre-surgery) as well as after [ADDRESS_34172] -surgery vaccinations . In previous research, 
the mean (± SD) number of SFC per 106 lymphocytes for cells cultured with no peptide in previous qualified 
assays has been 4.5 ± 3.6 . The mean (± SD) response for cells cul tured with an irrelevant peptide ( i.e., 
actin) has been determined to be 4.2 ± 6.3. Values for cells cultured with IDH1 peptide, after subtraction of 
counts from cells cultured with no peptide, will be determined. A response will be considered positive if this 
value is greater than 20 SFC per 106 lymphocytes after determining the level of detection in the IDH 
ELISpot . With 20 patients, there is 80% power to detect a difference of 4.[ADDRESS_34173] for multiplicity.  
15.6 Exploratory Objectives  
Exploratory  objectives  include:  (1) e stimation of overall survival and progression- free survival , (2) 
examination of the effect of ELISpot results on subsequent OS or PFS , (3) estimation of the radiographic 
response rate, (4) d etermination of whether tumors are IDH1 negative at surgery,  (5) characterization of 
immunologic cell infiltrate, ( 6) determination of whether  IDH R132H can be detected in plasma and whether 
the study treatment will affect the levels detected, ( 7) determination of whether IDH 2HG can be detected 
in plasma and whether the study treatment will affect levels detected, ( 8) genomic  and proteomic analyses , 
and ( 9) an assessment of metabolic imaging.  
 
1. The Kaplan- Meier estimator will describe the survival , PFS from vaccine #1, and PFS post -resection of 
patients treated with PEP IDH1M vaccine. Survival is defined as the time between first vaccine and death, 
or last follow -up if the patient remains alive. PFS from vaccine #1 is defined as the time between vaccine 
#[ADDRESS_34174]-resection is similarly defined but starting at resection.  
The proportion of patients alive without progression 6 months after resection will be estimated from the Kaplan -Meier estimator.  
2. Cox proportional hazards model will be used to explore the association between ELISpot outcome and 
subsequent OS or PFS.  The radiographic response rate (complete response + partial response) will be 
estimated with a 95% confidence interval .  
3. The proportion of tumors that are IDH1 negative at the time of surgery will be estimated, with a 95% confidence interval.  
4. Means and standard deviations, as well as quantiles, will be used to describe the distribution of 
immunologic cell infiltrates found in tumors at the time of surgery.  
5. Descriptive statistics will be used to describe the changes over time in the level of IDH R132H as 
measured from tumor -specific circulating DNA .   
6. In a similar manner , changes over time in levels of the 2- HG metabolite as measured by [CONTACT_34568].    
7. Genomic and proteomic analyses of the pre- treatment pathologic specimen and the post -vaccination 
surgical sample will be conducted.  Changes in geneti c alterations, differential protein expressions and 
PTMs will be described.  If statistical tests are conducted, appropriate adjustment for multiplicity will be 
considered.  
8. Measures of metabolism in IDH1+ gliomas will be assessed at several time point s.  Paired comparison 
(e.g. paired t -tests) will be used to assess whether same- day measures on a patient are the same.  
Assuming repeatability, changes over time in levels of metabolism will be described.  
 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 44 
 CONFIDENTIAL  
 Additional exploratory analyses may be conducted .  Among these additional exploratory analyses will be 
an examination of the relationship among changes in metabolism, genomic expression, 2- HG metabolite, 
and pathologic expression of IDH . 
15.7 Interim Analysis  
Efficacy : No interim efficacy analysis is planned.  
Safety : See section 15.4.2.  
15.[ADDRESS_34175] research design or data analysis ( i.e., amendments affecting subject 
population, inclusion/exclusion criteria, agent administration, statistical analysis, etc.).  
The Principal Investigator [INVESTIGATOR_12604]- approval from the IRB within [ADDRESS_34176]’s 
study records, and a copy of the informed consent form will be provided to th e subject . The Principal 
Investigator [INVESTIGATOR_12605]/her primary care 
physician about participation in the study . If the subject agrees to such notification, the Principal Investigator 
[INVESTIGATOR_34508]’s primary care physician about the subject’s participation in the clinical study.  
The prospective participant will have as much time as he/she may need to make an informed decision 
about the study and all treatment related questions will b e answered. Prospective participants will be 
consented in an exam room where it is just the research staff, the patient and his/her family, if so desired by [CONTACT_102] . Before, during, and after the consent is signed, the research team and investigators will be 
available in person and by [CONTACT_34569] . Any and all other 
available treatment options are offered to the patient in order to avoid undue influence. Participants are not 
offered compensation for this study  in order to avoid any monetary coercion/influence.  
Pro00054746: RESIST Study  
Version: [ADDRESS_34177] decides to part icipate, they 
will sign the consent form, or if they are unable to sign, make another kind of mark (like an X) to indicate 
consent . The person obtaining consent will document at the bottom of the consent form that the consent 
form was read out loud to the patient by (name [CONTACT_34589]) . If an X or mark is used instead 
of a signature, the person obtaining consent will note on the consent form that the subject wrote a mark or 
X instead of a signature. The witness will sign the consent form. Subjects who do not read/understand 
English may be potentially enrolled following DUHS HRPP policy, including obtaining IRB approval of either 
a short form or long form consent translation.  
All of the potential subjects are patients of the PI [INVESTIGATOR_34509] . Patients will be recruited for this 
study as follows : Upon determination that a patient’s tumor histology and radiographic findings are 
compatible with the eligibility criteria of this protocol, the clinical study will be briefly explained to the patient 
by [CONTACT_458] (PI) or colleague. If the patient indicates interest in study participation, patient 
education sheets and possibly the protocol consent form will be provided to the patient as these provide 
the most comprehensive explanation of  the study in lay terms. If the patient shows continued interest, the 
PI [INVESTIGATOR_34510]/exclusion criteria, risks, benefits and alternatives to study 
participation.  
16.[ADDRESS_34178]’s data will 
be maintained. RDSPs will be approved by [CONTACT_34570].  
To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the 
course of the study . Prospective participants will be consented in an exam room where it is just the research 
staff, the patient and his family, if desired. For all future visits, interactions with research staff (study doctor and study coordinators) regarding research activities will take place in a private exam room. All research 
related interactions with the participant will  be conducted by [CONTACT_34571].  
To protect confidentiality, subject files in paper format will be stored in secure cabinets under lock and 
key accessible only by [CONTACT_16133]. Subjects will be identified only by a unique study number and 
subject initials . Electronic records of subject data will be maintained using an electronic  database housed 
by [CONTACT_34572] . Access to electronic databases will be limited to protocol personnel.  Data stored on portable 
memory devices will be de- identified . The security and viability of the IT infrastructure will be managed by 
[CONTACT_33678]/or Duke Medicine.  
Upon completion of the study, research records will be archived and handled per DUHS HRPP policy .  
Subject names or identifiers will not be used in reports, presentations at scientific meetings, or 
publications in scientific journals.  
16.5 Data and Safety Monitoring  
Data and Safety Monitoring will be performed in accordance with the DCI Data and Safety Monitoring 
Plan.  
The Principal Investigator, CPC and DUHS IRB assess the adequacy of proposed Data and Safety 
Monitoring Plans during initial and ongoing review and ensure inclusion of adverse event reporting 
guidelines in each protocol. The sponsor -inves tigator is responsible for reporting all applicable events to 
the appropriate regulatory agencies as described in the protocol.  
Protocols sponsored by [CONTACT_34573] (e.g., ECOG, GOG, NSABP, ADOSOG, 
SWOG, RTOG, and CTSU) are monitored by  [CONTACT_34574].  
Phase III and IV protocols (e.g., NIH -supported, large- scale, multi -site phase III therapeutic intervention 
protocols which involve significant risk) are outside th e scope of this monitoring and safety review system. 
Independent DSMBs for such studies should be established by  [CONTACT_456] -investigator. NIH -supported 
phase III clinical protocols which involve only low risk (e.g. behavioral and nutritional interventions ) will be 
reviewed by [CONTACT_34575] a case -by- case basis, as their sample size may be too large to be practically 
monitored by [CONTACT_34576].  
Pro00054746: RESIST Study  
Version: [ADDRESS_34179], or the data may be submitted simultaneously with required reporting, 
e.g., FDA annual report. Attachments (e.g., accrual tables, toxicities and reference literature) are also 
acceptable for Safety Oversight Committee review . The sponsor -investigator is notified in writing if 
additional information is needed and if protocol or operational changes are required. The Safety Oversight 
Committee will notify the sponsor -investigator and DUHS IRB when significant safety concerns are 
identified. The Safety Oversight Committee Chair has the authority to temporarily suspend accrual to the 
study pending acceptable changes. Any recommendation for temporary or permanent suspension of an 
NIH-funded clinical protocol will be reported by [CONTACT_456] -investigator via written communication to the 
responsible NCI grant program director.  
 
DCI Monitoring Team  
The DCI Monitoring Team is comprised of individuals who do not have a direct wor king relationship 
with the sponsor -investigator or research team. This independence of DCI Monitoring Team composition is 
intended to prevent conflicts of interest and breaches of confidentiality during monitoring visits.  
The DCI Monitoring Team conducts m onitoring visits as defined by [CONTACT_34577], on DUHS sponsor -
investigator therapeutic intervention and prevention intervention studies that do not have an external 
monitoring plan, ensuring subject safety and that the protocol is conducted, recorded and reported in 
accordance with the protocol, SOPs, GCP, and applicable regulatory requirements. The Monitoring Team also provides ongoing education and resources to investigators and study teams to enhance the quality.  
Standard monitoring for therapeutic intervention an d prevention intervention studies is routine 
monitoring after the third subject is enrolled, followed by [CONTACT_12636]  1-[ADDRESS_34180] 
monitoring plan, as summarized in Table 1 on the next page. Also, additional monitoring may be prompted 
by [CONTACT_12637], unexpected frequency of serious and/or unexpected toxicities, or other 
concerns and may be initiated upon request of DUHS and DCI Leadership, CPC, Safety Oversight 
Committee, a  sponsor, an investigator or the IRB.  
SOC members serve as an expert resource and back -up for the DCI Monitoring Team. The DCI 
Monitoring Team reviews the adequacy of informed consent, enrollment of appropriate patients, 
implementation of protocol -specifie d procedures  and treatment, adequacy of data collection, and 
appropriateness of adverse event monitoring and reporting . 
16.[ADDRESS_34181] research design or data analysis (i.e. , amendments affecting subject population, inclusion/exclusion 
criteria, agent administration, etc.).  
16.7 Records Retention  
The Principal Investigator [INVESTIGATOR_12608] -related records  for the longer of a period of:  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 47 
 CONFIDENTIAL  
 • at least two years after the date on which a New Drug Application is approved by [CONTACT_1622]  
• at least two years after formal withdrawal of the IND associat ed with this protocol  
• at least six years after study completion (Duke policy)  
16.[ADDRESS_34182] appointments, publicly -traded or privately -held equities, stock 
options, intellectual property, and gifts.  
The Duke University School of Medicine’s RIO reviews and manages research -related conflicts  of 
interest . The Principal Investigator [INVESTIGATOR_34511]- Investigators must report conflicts of interest annually and 
within [ADDRESS_34183] a documented management plan 
that is developed in conjunction with the Duke R IO and approved by [CONTACT_1201]/IEC.  
16.[ADDRESS_34184] party payer (HMO or insurance company) will be 
responsible for all other medical costs including the standard of care chemotherapy , radiation therapy (if 
applicable) , blood work, and MRI scans . Some insurance companies and HMOs may not  reimburse patients 
for costs arising from investigational studies . No compensation for participation in this study will be given.  
16.[ADDRESS_34185] registration will be entered 
into the Velos e- Research software system . This system is managed by [CONTACT_34578].  Patients 
will also be entered under this protocol  study  in the Duke Epic Maestro Care system .  
 
  
Pro00054746: RESIST Study  
Version: [ADDRESS_34186] L, Yang JC, Hughes MS, Kammula US, 
Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, 
Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, 
Nathan DA, Laurencot CM, Rosenberg SA. Gene the rapy with human and mouse T -cell 
receptors mediates cancer regression and targets normal tissues expressing cognate 
antigen. Blood. 114(3):535- 46, 2009. PMCID: PMC2929689.  
2. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM. Succes sful treatment of melanoma brain metastases with adoptive cell therapy. Clin 
Cancer Res. 16(19):4892- 8, 2010.  
3. 
Estimated New Cancer Deaths by [CONTACT_34579], US, 2012: American Cancer Society; 2012 
[August 31st 2012]. Available from: http://www.cancer.org/acs/groups/content/@epi[INVESTIGATOR_27835]/documents/document/acspc -032009.pdf . 
4. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary 
malignant brain tumors stratified by [CONTACT_34580]: an analysis 
based on Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) data, 1973- 1991. J 
Neurosurg. 88(1):1- 10, 1998.  
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, 
Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, 
Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352(10):987- 96, 
2005.  
6. Imperato JP, Paleologos NA, Vi ck NA. Effects of treatment on long -term survivors with 
malignant astrocytomas. Ann Neurol. 28(6):818- 22, 1990.  
7. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT, Jr. Sequential immunotherapy by [CONTACT_28835] -CSF-expressing glioma cells and CTLA -4 blockade effectively treats 
established murine intracranial tumors. J Immunother. 35(5):385 -9, 2012. PMCID: 
PMC3352987.  
8. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, 
Allison JP, Bigner DD, Sampson JH. Systemic CTLA -4 blockade ameliorates glioma -
induced changes to the CD4+ T cell compartment without affecting regulatory T -cell 
function. Clin Cancer Res. 13(7):2158- 67, 2007.  
9. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert 
MR, Herndon JE, 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling 
RJ, Shi W, Vredenburgh JJ, Bigner DD. Immunologic escape after prolonged progression-
free survival with epi[INVESTIGATOR_34512]. J Clin Oncol. 28(31):4722- 9, 2010. PMCID: 
PMC3020702.  
10. Atkinson WL, Pi[INVESTIGATOR_34513], Schwartz B, Weniger BG, Iskander JK, Watson JC, Centers for Disease C, Prevention. General recommendations on immunization. 
Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the 
American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 51(RR -2):1-35, 
2002.  
11. Myers MG, Beckman CW, Vosdingh RA, Hankins WA. Primary immunization with tetanus 
and diphtheria toxoi ds. Reaction rates and immunogenicity in older children and adults. 
JAMA. 248(19):2478 -80, 1982.  
12. Baxter D. Active and passive immunity, vaccine types, excipi[INVESTIGATOR_34514]. Occup 
Med (Lond). 57(8):552- 6, 2007.  
Pro00054746: RESIST Study  
Version: [ADDRESS_34187] of epi[INVESTIGATOR_34515]. Clin Cancer Res. 11(4):1462- 6, 2005.  
14. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, 
Dranoff G, Friedman AH, Friedman HS, Bigner DD. Unarmed, tumor -specific monoclonal 
antibody effectively treats brain tumors. Proc Natl Acad Sci U S A. 97(13):7503- 8, 2000. 
PMCID: PMC16575.  
15. Heimberger AB, Crotty LE, Archer GE, Hes s KR, Wikstrand CJ, Friedman AH, Friedman 
HS, Bigner DD, Sampson JH. Epi[INVESTIGATOR_34516]. Clin Cancer Res. 9(11):4247- 54, 
2003.  
16. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, 
Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling 
R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB. Greater chemotherapy -induced 
lymphopenia enhances tumor -specific imm une responses that eliminate EGFRvIII -
expressing tumor cells in patients with glioblastoma. Neuro Oncol. 13(3):324 -33, 2011. 
PMCID: PMC3064599.  
17. Mehta AI, Persson O, Herndon JE, Archer GE, McLendon R, Heimberger AB, Mitchell DA, Bigner DD, Sampson JH. R eply to M.S. Lesniak. J Clin Oncol. 29(22):3105- 6, 2011.  
18. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate- pulsed dendritic cells can elicit an 
effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci 
U S A. 99(2):931 -6, 2002. PMCID: PMC117408.  
19. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian 
SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, 
Rogers -Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer 
regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298(5594):850- 4, 2002. PMCID: PMC1764179.  
20. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after 
the trans fer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. [ADDRESS_34188] 
2:[ZIP_CODE]- 45, 2004. PMCID: PMC521998.  
21. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, 
Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ,  Jones SA, Mangiameli 
DP, Pelletier MM, Gea -Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, 
Rosenberg SA. Adoptive cell transfer therapy following non -myeloablative but 
lymphodepleting chemotherapy for the treatment of patients with refractory met astatic 
melanoma. J Clin Oncol. 23(10):2346 -57, 2005. PMCID: PMC1475951.  
22. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, 
Westphal S, Mair R, Chi N, Ratterree B, Pochran MF, Natt S, Hinkle J, Sickles C, Sohal 
A, Rue hle K, Lynch C, Zhang L, Porter DL, Luger S, Guo C, Fang HB, Blackwelder W, 
Hankey K, Mann D, Edelman R, Frasch C, Levine BL, Cross A, June CH. Restoration of immunity in lymphopenic individuals with cancer by [CONTACT_34581] T- cell 
transfer. Nat Med. 11(11):1230 -7, 2005.  
23. Grossman Z, Paul WE. Self -tolerance: context dependent tuning of T cell antigen 
recognition. Semin Immunol. 12(3):197 -203; discussion 57- 344, 2000.  
24. Tanchot C, Rosado MM, Agenes F, Freitas AA, Rocha B. Lymphocyte homeostasi s. 
Semin Immunol. 9(6):331- 7, 1997.  
25. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis -stimulated proliferation drives 
naive T cells to differentiate directly into memory T cells. J Exp Med. 192(4):549 -56, 2000. 
PMCID: PMC2193235.  
Pro00054746: RESIST Study  
Version: [ADDRESS_34189]. 110(2):185 -92, 2002. PMCID: PMC151053.  
27. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development o f antitumor immune responses in 
reconstituted lymphopenic hosts. Cancer Res. 62(14):3914 -9, 2002.  
28. Robbins PF, Dudley ME, Wunderlich J, El -Gamil M, Li YF, Zhou J, Huang J, Powell DJ, 
Jr., Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes 
correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 
173(12):7125- 30, 2004. PMCID: PMC2175171.  
29. Rosenberg SA. Cancer immunotherapy comes of age. Nat Clin Pract Oncol. 2(3):115, 2005. PMCID: PMC2656369.  
30. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor -specific T -
cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 28(1):53 -62, 2005. PMCID: PMC2175172.  
31. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in 
melanoma patients receiving cell transfer therapy. J Immunol. 175(10):7046- 52, 2005 . 
PMCID: PMC1351312.  
32. Dudley ME, Rosenberg SA. Adoptive- cell-transfer therapy for the treatment of patients 
with cancer. Nat Rev Cancer. 3(9):666 -75, 2003. PMCID: PMC2305722.  
33. Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. 
Lancet Oncol. 6(1):3 -4, 2005. PMCID: PMC1484507.  
34. Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol 
Lett. 98(1):23- 31, 2005.  
35. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends -van der Meer DM, Vloon AP, 
Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren 
GJ, van der Burg SH, Melief CJ. Vaccination against HPV -16 oncoproteins for vulvar 
intraepi[INVESTIGATOR_28601]. N Engl J Med. 361(19):1838- 47, 2009.  
36. Gajewski TF. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol. 22(4):[ADDRESS_34190]. 25(4):249 -55, 2007.  
38. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, 
Sepkowitz KA, Chapman PB. Selective CD4+ lymphopenia in melanoma patients treated 
with temozolo mide: a toxicity with therapeutic implications. J Clin Oncol. 22(4):610- 6, 
2004.  
39. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an 
alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 25(22):3357-
61, 2007.  
40. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel 
JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins  KI, 
Tzuk -Shina T, Brown PD, Chakravarti A, Curran WJ, Jr., Mehta MP. Dose- dense 
temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J 
Clin Oncol. 31(32):4085- 91, 2013. PMCID: PMC3816958.  
41. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, 
Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson 
JH. Immunological responses in a patient with glioblastoma multiforme treated with 
sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 
10(1):98- 103, 2008. PMCID: PMC2600844.  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 51 
 CONFIDENTIAL  
 42. Slingluff CL, Jr., Speiser DE. Progress and controversies in developi[INVESTIGATOR_34517]. 
J Transl Med. 3(1):18, 2005. PMCID: PMC1142519.  
43. Pi[INVESTIGATOR_9387] L, Rivoltini L, Patuzzo R, Marra ri A, Valdagni R, Parmiani G. Multipeptide vaccination 
in cancer patients. Expert Opin Biol Ther. 9(8):1043- 55, 2009.  
44. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen -loaded antigen -
presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 7(8):1275- 80, 2007.  
45. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, 
Li Y, Kurlander R, Barrett AJ. Ex vivo characterization of polyclonal memory CD8+ T -cell 
responses to PRAME -specific peptides in pat ients with acute lymphoblastic leukemia and 
acute and chronic myeloid leukemia. Blood. 113(10):2245- 55, 2009. PMCID: 
PMC2652370.  
46. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi 
Y, Nakamura Y, Fujii H. Vaccination with m ultiple peptides derived from novel cancer -
testis antigens can induce specific T -cell responses and clinical responses in advanced 
esophageal cancer. Cancer Sci. 100(8):1502 -9, 2009.  
47. Schmitt M, Casalegno -Garduno R, Xu X, Schmitt A. Peptide vaccines for  patients with 
acute myeloid leukemia. Expert Rev Vaccines. 8(10):1415 -25, 2009.  
48. Knutson KL, Disis ML. Tumor antigen- specific T helper cells in cancer immunity and 
immunotherapy. Cancer Immunol Immunother. 54(8):721- 8, 2005.  
49. Odunsi K, Qian F, Matsu zaki J, Mhawech- Fauceglia P, Andrews C, Hoffman EW, Pan L, 
Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. 
Vaccination with an NY -ESO -1 peptide of HLA class I/II specificities induces integrated 
humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 104(31):[ZIP_CODE]-
42, 2007. PMCID: PMC1937553.  
50. Perez -Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 
cells can be more efficient at tumor rejection than CD8 cells. Blood. 109(12): 5346- 54, 
2007. PMCID: PMC1890845.  
51. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti -tumor immune responses. 
Immunol Rev. 222:129- 44, 2008.  
52. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T -cell help for 
cytotoxic T lymp hocytes is mediated by [CONTACT_398]40- CD40L interactions. Nature. 
393(6684):480- 3, 1998.  
53. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, 
Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, 
Rosenberg SA. Imm unization of patients with metastatic melanoma using both class I - 
and class II -restricted peptides from melanoma- associated antigens. J Immunother. 
26(4):349- 56, 2003. PMCID: PMC1679660.  
54. Slingluff CL, Jr., Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-
Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T- cell responses and clinical activity of a melanoma vaccine with multiple peptides 
from MAGE and melanocytic differentiation antigens. J Clin Onc ol. 26(30):4973- 80, 2008. 
PMCID: PMC2652084.  
55. Slingluff CL, Jr., Petroni GR, Chianese- Bullock KA, Smolkin ME, Ross MI, Haas NB, von 
Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma -
associated helper peptides and cyclophosphami de on the immunogenicity of a 
multipeptide melanoma vaccine. J Clin Oncol. 29(21):2924 -32, 2011. PMCID: 
PMC3138719.  
56. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ 
CTL priming by [CONTACT_34582][INVESTIGATOR_34518] e Freund's adjuvant induces a 
vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J 
Immunol. 179(8):5033 -40, 2007.  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 52 
 CONFIDENTIAL  
 57. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by 
[CONTACT_34583]. Nat Rev Cancer. 8(5):351- 60, 2008.  
58. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti 
B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, 
Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and 
interleukin -2 in patients with advanced melanoma. N Engl J Med. 364(22):2119- 27, 2011. 
PMCID: PMC3517182.  
59. Noguchi M, Moriya F, Suekane S, Mats uoka K, Arai G, Matsueda S, Sasada T, Yamada 
A, Itoh K. Phase II study of personalized peptide vaccination for castration- resistant 
prostate cancer patients who failed in docetaxel -based chemotherapy. Prostate. 
72(8):834- 45, 2012.  
60. Weber JS, Vogelzang N J, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, 
Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A. A phase 1 study of a vaccine targeting 
preferentially expressed antigen in melanoma and prostate -specific membrane antigen in 
patients with advanc ed solid tumors. J Immunother. 34(7):[ADDRESS_34191] murine intracerebral melanoma. Neurosurgery. 
50(1):158- 64; discussion 64- 6, 2002.  
62. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, 2nd, Lally -Goss D, 
McGehee- Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. 
An epi[INVESTIGATOR_34519] -targeted vaccine is safe and immunogenic 
in patients with glioblastoma multiforme. Mol Cancer Ther. 8(10):2773 -9, 2009. PMCID: 
PMC2991139.  
63. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Big ner DD. 
Characterization of a spontaneous murine astrocytoma and abrogation of its 
tumorigenicity by [CONTACT_34584]. Neurosurgery. 41(6):1365- 72; discussion 72- 3, 1997.  
64. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H , Siu 
IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam 
DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, 
Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, 
Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma 
multiforme. Science. 321(5897):1807- 12, 2008. PMCID: PMC2820389.  
65. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-[ADDRESS_34192] common glioma -derived mutation. 
Biochem Biophys Res Commun. 390(3):547- 51, 2009. PMCID: PMC2788025.  
66. Merritt TJ, Kuczynski C, Sezgin E, Zhu CT, Kumagai S, Eanes WF. Quantifying interactions within the NADP(H) enzyme networ k in Drosophila melanogaster. Genetics. 
182(2):565- 74, 2009. PMCID: PMC2691764.  
67. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the 
development of astrocytomas and oligodendrogliomas. Am J Pathol. 174(4):1149- 53, 
2009. PMCID: PMC2671348.  
68. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific 
for IDH1 R132H mutation. Acta Neuropathol. 118(5):599- 601, 2009.  
69. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessm er C, 
Korshunov A, Zentgraf H, Hartmann C, von Deimling A. Characterization of R132H mutation- specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1):245- 54, 2010.  
70. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic -Haberle I, 
Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 53 
 CONFIDENTIAL  
 Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J 
Med. 360(8):765 -73, 2009. PMCID: PMC2820383.  
71. Pi[INVESTIGATOR_34520], Reitman ZJ, Yan H. Rele asing the Block: Setting Differentiation Free with 
Mutant IDH Inhibitors. Cancer Cell. 23(5):570- 2, 2013.  
72. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez 
GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild- type IDH1 suppresses D -
2-hydroxyglutarate production in IDH1- mutated gliomas. Cancer Res. 73(2):496- 501, 
2013. PMCID: PMC3548957.  
73. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel -Wahab O, Edwards CR, Khanin 
R, Figueroa ME, Melnick A, Wellen KE, O'Rourke D M, Berger SL, Chan TA, Levine RL, 
Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483(7390):474- 8, 2012. PMCID: PMC3478770.  
74. Noushmehr H, Weisenberger DJ, Diefes K, Phillips  HS, Pujara K, Berman BP, Pan F, 
Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, 
Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope 
LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas 
Research N. Identification of a CpG island methylator phenotype that defines a distinct 
subgroup of glioma. Cancer Cell. 17(5):510- 22, 2010. PMCID: PMC2872684.  
75. Rohle D, Popovici -Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J , Clark 
O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang 
F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, 
Chan TA, Graeber TG, Yen KE, Mellinghoff IK. An inhibitor of mutant IDH1 delays growth 
and promotes differentiation of glioma cells. Science. 340(6132):626- 30, 2013.  
76. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root 
DE, Ebert BL, Kaelin WG, Jr. (R) -2-hydroxyglutarate is sufficient to promote 
leukemogenesis and its effects are reversible. Science. 339(6127):1621- 5, 2013.  
77. Duncan CG, Barwick BG, Jin G, Rago C, Kapoor -Vazirani P, Powell DR, Chi JT, Bigner 
DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome- wide 
alterations i n DNA methylation. Genome Res. 22(12):2339- 55, 2012. PMCID: 
PMC3514664.  
78. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, 
Cantley LC, Tho mpson CB, Vander Heiden MG, Su SM. Cancer -associated IDH1 
mutations produce 2- hydroxyglutarate. Nature. 462(7274):739- 44, 2009. PMCID: 
PMC2818760.  
79. Jin G, Pi[INVESTIGATOR_34520], Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He 
Y, Yan H. Mutant IDH 1 is required for IDH1 mutated tumor cell growth. Oncotarget. 
3(8):774- 82, 2012. PMCID: PMC3478455.  
80. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2- hydroxyglutarate in IDH -mutated glioma  patients by [CONTACT_34585] -editing and 2D correlation magnetic resonance spectroscopy. Sci Transl 
Med. 4(116):116ra4, 2012.  
81. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, M ikkelsen T, Wong ET, Chamberlain MC, 
Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response 
assessment criteria for high- grade gliomas: response assessment in neuro- oncology 
working group. J Clin Oncol. 28(11):1963 -72, 2010.  
82. Boisselier B, Gallego Perez -Larraya J, Rossetto M, Labussiere M, Ciccarino P, Marie Y, 
Delattre JY, Sanson M. Detection of IDH1 mutation in the plasma of patients with glioma. 
Neurology. 79(16):1693- 8, 2012.  
Pro00054746: RESIST Study  
Version: [ADDRESS_34193] relapse. Br 
J Cancer. 83(5):588- 93, 2000. PMCID: PMC2363506.  
 
 
  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 55 
 CONFIDENTIAL  
 18 APPENDICES  
18.1 Protocol Synopsis and Summary  
Please see separate documents (available upon request).  
 
 
 
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 77 
 CONFIDENTIAL  
 18.2 Special or Representative SOPs and FORMs 
Please see separate document s (available upon request).  
  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 78 
 CONFIDENTIAL  
 18.3 DSMBplus Monitoring Plan  
Please see separate document (available upon request).  
 
 
  
Pro00054746: RESIST Study  
Version: [ADDRESS_34194] Radiation Therapy  
Radiotherapy typi[INVESTIGATOR_34521] ≤ 5 weeks of surgery. One treatment of 1.8- 2.0 Gy/fraction should 
be given daily 5 days per week for a total of 59.4- 60.0 Gy over <7 weeks. 3D conformal and intensity -
modulated RT is permitted. All portals should be treated during each treatment session. Doses are specified 
as the target dose that shall be to the center of the target volume.  
 The gross target volume (GTV) for both the initial volume (GTV1) and the conedown volume (GTV2) 
should be based on the postoperat ive CT/MRI (and preferably the MRI; the preoperative scans may be 
used if postoperative scans are not available). This initial target volume (GTV1) should include the contrast -
enhancing lesion (and should include the surgical resection cavity) and surrounding edema (if it exists) demonstrated on CT/MRI plus a 2.0- cm margin (this 2.0- cm margin- extended volume will be considered 
the initial planning target volume, or PTV1). The initial target volume should be treated to 46 Gy at 
2Gy/fraction or 45- 50.4 Gy at 1.8Gy/fraction. If no surrounding edema is present, the initial planning target 
volume (PTV1) should include the contrast -enhancing lesion (and should include the surgical resection 
cavity) plus a 2.5- cm margin. Please note that clinical judgment may be us ed to modify PTV1 to exclude 
sensitive structures such as the optic chiasm, non- cranial contents, or anatomic regions in the brain where 
natural barriers would likely preclude microscopic tumor extension, such as the cerebellum, the 
contralateral hemispher e, directly across from the tentorium cerebri, the ventricles, etc. After 46 Gy, the 
tumor volume (GTV2) for the conedown treatment should include the contrast -enhancing lesion (without 
edema) on the pre- surgery CT/MRI scan plus a 1.5- 2-cm margin (PTV2). T reat to 14 Gy at 2Gy/fraction or 
14.4- 9.0 Gy at 1.8Gy/fraction to a total of 60.[ADDRESS_34195] 95% of the target volume receives he prescribed 
dose.  
 The optic apparatus should be limit ed to a maximum of 54Gy and no more than 5% of the volume of 
the brainstem should receive >54Gy.  
 Radiation should be delayed or interrupted if the platelet count is < 20,000. Radiation should not begin 
or resume until the platelet count is ≥ 20,000. Hemat ologic toxicities should be rated on a scale of 0- 5 as 
defined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.  If radiotherapy 
has to be temporarily interrupted for technical or medical reasons unrelated to the temozolomide 
administration, then treatment with daily temozolomide should continue. If radiotherapy has to be 
permanently interrupted then treatment with daily temozolomide should stop.  The following should be 
recorded at entry into this study: daily treatment record, all isodose distributions (in color), dose volume 
histograms including the cumulative dose to the target volumes, optic chiasm, optic nerves and brain stem, 
and the radiotherapy summary.  
  
Pro00054746: RESIST Study  
Version: [ADDRESS_34196] external beam RT under the direction of the study Neuro- Oncologists (listed on title page), or 
their designees, respectively, at Duke University or another institut ion at the standard dose per discretion 
of the treating neuro- oncologist.  During standard RT, s ubjects will receive 75mg/m2/day TMZ for 42 days 
(6 weeks).  
 
Per the new NCI Temozolomide (NSC 362856) Action Letter:  
o Liver function tests (or CMP) should be performed:  
 prior to treatment initiation. If abnormal, the decision to initiate temozolomide 
treatment should carefully consider the benefits and risks for the individual patient;  
 after each treatment cycle.  
o For patients on a [ADDRESS_34197] 
during this cycle;  
o For patients with significant liver function abnormalities the benefits and risks of continuing 
treatment should be carefully considered.  
 If any interruption occurs or dose reduction is required,  TMZ may be resumed when re- treatment criteria 
are met as outlined in Table 5 and Table 6.   
 Dose reduction or alteration during this period due to toxicity is standardly performed as outlined in 
Table 5. 
 
Table 5: Temozolomide Dosing Interruption or Discontinuation during Concomitant Radiotherapy  
Toxicity  TMZ Interruptiona  TMZ Discontinuation  
Absolute Neutrophil Count  >0.5 and <1.0 x 109/L  <0.5 x 109/L  
Platelet Count  >10 and <100 x 109/L  <10 x 109/L  
Common toxicity criteria (CTC2) Non -
hematological Toxicity (except for alopecia, 
nausea, vomiting)  CTC Grade 2  CTC Grade 3 or 4  
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: 
absolute neutrophil count >1.0 x 109/L; platelet count > 100 x 109/L; CTC non-  hematological toxicity 
<Grade 1 (except for alopecia, nausea, vomiting).  
 
The dose may be modified as outlined in Table [ADDRESS_34198].  
 
Table 6. Dose Modifications of Temozolomide during Radiation Therapy  
Dose at Toxicity  Modified Dose  
75 mg/m2 (during XRT)  60 mg/m2  
60 mg/m2 (during XRT)  50 mg/m2  
 
18.5.2  Guidelines for 21-day  TMZ Therapy  
Subjects with stable histologic grade at time of surgery (Grade 2) will  be treated with adjuvant TMZ  at 
a targeted dose of 50- 100mg/m2/day for [ADDRESS_34199]  a 3 ± 1 week break before  
                                                      
2 CTC, common toxicity criteria (NCI)  
Pro00054746: RESIST Study  
Version: 20171011 
PT-PhI-II v05.22.12  Duke Cancer Institute  Page 81 
 CONFIDENTIAL  
 resum ing TMZ ( Table 7). Then, subjects  should receive TMZ at a target ed dose of 50-100 mg/m2/day for 
21 days  every 28 days  for up to 12 cycles .  A CBC  with auto differential (Lab Code 2010300) should be 
obtained at the end of each cycle for all subjects receiving  21-day TMZ . 
 
Table 7. Criteria to Resume Temozolomide after Radiation  
Absolute Neutrophil Count ≥ 1.0 x 109/L 
Platelet Count ≥ 100 x 109/L 
Resolution of CTC Non -hematologic toxicities to Grade [ADDRESS_34200] will also 
be recommended before the initial doses of concomitant TMZ and may be used during the adjuvant 21- day 
course of TMZ.  
 
All subjects will start 21- day TMZ cycle 1 at a dose of 50mg/m2/day, and the dose may be increased  
up to 100mg/m2/day in subsequent cycles at the discretion of the treating physician.  During 21-day TMZ 
treatment (28 day cycles ), dose adjustments to TMZ, if needed, may be conducted as outlined below:  
 
Table 8. Temozolomide Dose Delay, Reduction , or Discontinuation During 21-day Treatment  
Toxicity  Delay TMZ Dose  a Reduce TMZ by 25%  
(down to minimum of 50 
mg/m2) b Discontinue TMZ  
Absolute Neutrophil Count  >0.5 and <1.0 x 109/L >0.5 and <1.0 x 109/L <0.5 x 109/L  
Platelet Count  >10 and <100 x 109/L >10 and <100 x 109/L <10 x 109/L  
CTC Non -hematological 
Toxicity (except for 
alopecia, nausea, vomiting)  CTC Grade 3  CTC Grade 3  CTC Grade 4 c  
 a: If dose is delayed, treatment with TMZ can resume when the following 
conditions are met: absolute neutrophil count >1.0 x 109/L; platelet count 
>100 x 109/L; CTC non- hematological toxicity resolved  to baseline (except 
for alopecia, nausea, vomiting).  
b: For subjects whose dose was escalated above 50 mg/m2 at the discretion 
of treating physician  
c: TMZ is to be discontinued if dose reduction to < 50 mg/m2 is required or if 
the same Grade 3 non- hematological toxicity (except for alopecia, nausea, 
vomiting) recurs after dose reduction  or delay .   
 
 
 